<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vitamin D for the management of multiple sclerosis - Jagannath, VA - 2018 | Cochrane Library</title> <meta content="Vitamin D for the management of multiple sclerosis - Jagannath, VA - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008422.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vitamin D for the management of multiple sclerosis - Jagannath, VA - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008422.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008422.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Vitamin D for the management of multiple sclerosis" name="citation_title"/> <meta content="Vanitha A Jagannath" name="citation_author"/> <meta content="American Mission Hospital" name="citation_author_institution"/> <meta content="kidzdoc311@gmail.com" name="citation_author_email"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Carlo Besta Foundation and Neurological Institute" name="citation_author_institution"/> <meta content="Israel Junior Borges do Nascimento" name="citation_author"/> <meta content="Universidade Federal de Minas Gerais (UFMG)" name="citation_author_institution"/> <meta content="Carlo Di Pietrantonj" name="citation_author"/> <meta content="Local Health Unit Alessandria- ASL AL" name="citation_author_institution"/> <meta content="Edward W Robak" name="citation_author"/> <meta content="University of New Brunswick" name="citation_author_institution"/> <meta content="Liz Whamond" name="citation_author"/> <meta content="Canadian Cancer Action Network" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD008422.pub3" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/09/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008422.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008422.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008422.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cholecalciferol [*therapeutic use]; Ergocalciferols [*therapeutic use]; Fatigue [drug therapy]; Multiple Sclerosis [*drug therapy]; Quality of Life; Randomized Controlled Trials as Topic; Vitamins [*therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008422.pub3&amp;doi=10.1002/14651858.CD008422.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6zFwvAqw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008422\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008422\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","ko","ms","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008422.pub3",title:"Vitamin D for the management of multiple sclerosis",firstPublishedDate:"Sep 24, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008422.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008422.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008422.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008422.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008422.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008422.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008422.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008422.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008422.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008422.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>14348 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008422.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/appendices#CD008422-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/supinfo/CD008422-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/supinfo/CD008422-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vitamin D for the management of multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vanitha A Jagannath</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0005">Graziella Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0006">Israel Junior Borges do Nascimento</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0007">Carlo Di Pietrantonj</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0008">Edward W Robak</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information#CD008422-cr-0009">Liz Whamond</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information/en#CD008422-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 September 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008422.pub3">https://doi.org/10.1002/14651858.CD008422.pub3</a> </div> </div> </header> <div class="editorialNote"> <section id="CD008422-note-0001"> <p> <b>Editorial note</b> </p> <p>No update planned, no new version forthcoming</p> </section> </div> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008422-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008422-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008422-abs-0006">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008422-abs-0001" lang="en"> <section id="CD008422-sec-0001"> <h3 class="title" id="CD008422-sec-0001">Background</h3> <p>This review is an update of a previously published review, "Vitamin D for the management of multiple sclerosis" (published in the Cochrane Library; 2010, Issue 12). Multiple sclerosis (MS) is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the central nervous system (CNS), which can result in varying levels of disability. Some studies have provided evidence showing an association of MS with low levels of vitamin D and benefit derived from its supplementation. </p> </section> <section id="CD008422-sec-0002"> <h3 class="title" id="CD008422-sec-0002">Objectives</h3> <p>To evaluate the benefit and safety of vitamin D supplementation for reducing disease activity in people with MS. </p> </section> <section id="CD008422-sec-0003"> <h3 class="title" id="CD008422-sec-0003">Search methods</h3> <p>We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Specialized Register up to 2 October 2017 through contact with the Information Specialist with search terms relevant to this review. We included references identified from comprehensive electronic database searches and from handsearches of relevant journals and abstract books from conferences. </p> </section> <section id="CD008422-sec-0004"> <h3 class="title" id="CD008422-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared vitamin D versus placebo, routine care, or low doses of vitamin D in patients with MS. Vitamin D was administered as monotherapy or in combination with calcium. Concomitant interventions were allowed if they were used equally in all trial intervention groups. </p> </section> <section id="CD008422-sec-0005"> <h3 class="title" id="CD008422-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed the methodological quality of studies, while another review author sorted any disagreements. We expressed treatment effects as mean differences (MDs) for continuous outcomes (Expanded Disability Status Scale and number of magnetic resonance imaging (MRI) gadolinium‐enhancing T1 lesions), as standardised MDs for health‐related quality of life, as rate differences for annualised relapse rates, and as risk differences (RDs) for serious adverse events and minor adverse events, together with 95% confidence intervals (CIs). </p> </section> <section id="CD008422-sec-0006"> <h3 class="title" id="CD008422-sec-0006">Main results</h3> <p>We identified 12 RCTs enrolling 933 participants with MS; 464 were randomised to the vitamin D group, and 469 to the comparator group. Eleven trials tested vitamin D₃, and one trial tested vitamin D₂. Vitamin D₃ had no effect on the annualised relapse rate at 52 weeks' follow‐up (rate difference ‐0.05, 95% CI ‐0.17 to 0.07; I² = 38%; five trials; 417 participants; very low‐quality evidence according to the GRADE instrument); on the Expanded Disability Status Scale at 52 weeks' follow‐up (MD ‐0.25, 95% CI ‐0.61 to 0.10; I² = 35%; five trials; 221 participants; very low‐quality evidence according to GRADE); and on MRI gadolinium‐enhancing T1 lesions at 52 weeks' follow‐up (MD 0.02, 95% CI ‐0.45 to 0.48; I² = 12%; two trials; 256 participants; very low‐quality evidence according to GRADE). Vitamin D₃ did not increase the risk of serious adverse effects within a range of 26 to 52 weeks' follow‐up (RD 0.01, 95% CI ‐0.03 to 0.04; I² = 35%; eight trials; 621 participants; low‐quality evidence according to GRADE) or minor adverse effects within a range of 26 to 96 weeks' follow‐up (RD 0.02, 95% CI ‐0.02 to 0.06; I² = 20%; eight trials; 701 participants; low‐quality evidence according to GRADE). Three studies reported health‐related quality of life (HRQOL) using different HRQOL scales. One study reported that vitamin D improved ratings on the psychological and social components of the HRQOL scale but had no effects on the physical components. The other two studies found no effect of vitamin D on HRQOL. Two studies reported fatigue using different scales. One study (158 participants) reported that vitamin D₃ reduced fatigue compared with placebo at 26 weeks' follow‐up. The other study (71 participants) found no effect on fatigue at 96 weeks' follow‐up. Seven studies reported on cytokine levels, four on T‐lymphocyte proliferation, and one on matrix metalloproteinase levels, with no consistent pattern of change in these immunological outcomes. The randomised trials included in this review provided no data on time to first treated relapse, number of participants requiring hospitalisation owing to progression of the disease, proportion of participants who remained relapse‐free, cognitive function, or psychological symptoms. </p> </section> <section id="CD008422-sec-0007"> <h3 class="title" id="CD008422-sec-0007">Authors' conclusions</h3> <p>To date, very low‐quality evidence suggests no benefit of vitamin D for patient‐important outcomes among people with MS. Vitamin D appears to have no effect on recurrence of relapse, worsening of disability measured by the Expanded Disability Status Scale (EDSS), and MRI lesions. Effects on health‐related quality of life and fatigue are unclear. Vitamin D₃ at the doses and treatment durations used in the included trials appears to be safe, although available data are limited. Seven ongoing studies will likely provide further evidence that can be included in a future update of this review. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008422-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008422-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008422-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD008422-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD008422-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008422-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008422-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008422-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008422-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008422-abs-0002" lang="en"> <h3>Vitamin D for the management of multiple sclerosis</h3> <p><b>Review question</b><br/>Does vitamin D supplementation reduce disease activity in people with multiple sclerosis (MS)? </p> <p><b>What is the issue?</b><br/>Several epidemiological, immunological, and genetic studies have reported an association between low vitamin D, measured as low blood 25‐hydroxyvitamin D levels, and MS before and after the disease is triggered. Hence people with MS are screened for vitamin D deficiency, and vitamin D preparations are given along with immunomodulatory therapy. Whether vitamin D supplementation improves relevant clinical outcomes (recurrence of relapse, worsening of disability) or decreases the number of lesions observed by magnetic resonance imaging (MRI) is not clear. </p> <p><b>What did we do?</b><br/>We evaluated the benefits and harms of vitamin D in people with MS. We included randomised controlled trials (RCTs) and quasi‐RCTs that compared the effects of vitamin D supplementation versus placebo, routine care, or low doses of vitamin D. </p> <p><b>What did we find?</b><br/>Our systematic search identified 12 studies enrolling 933 people with MS. Research shows that vitamin D has no effect on recurrence of relapse, worsening of disability measured by the Expanded Disability Status Scale (EDSS), or new MRI gadolinium‐enhancing T1 lesions. Its effects on health‐related quality of life and fatigue are unclear. Our confidence in these results is very low because vitamin D has been evaluated in only a few small trials that we judged as having high risk of bias. Vitamin D supplementation appears to be safe for people with MS included in our review, but available data are limited. </p> <p><b>Conclusions</b><br/>For people with MS, vitamin D supplementation appears to have no effect on relevant clinical outcomes or new MRI lesions. Vitamin D supplementation at the doses and treatment durations used in the included trials appears to be safe, although available data are limited. Seven trials are ongoing; they will likely provide further evidence for a future update of this review. </p> <p><b>Currentness of evidence</b><br/>This evidence is up‐to‐date as of October 2017. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008422-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-sec-0087">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-sec-0168">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008422-sec-0087"></div> <h3 class="title" id="CD008422-sec-0088">Implications for practice</h3> <section id="CD008422-sec-0088"> <p>The results of this review show that vitamin D supplementation, irrespective of the form and dose used, provides no apparent benefit for people with MS. Moreover, short‐term trials have provided scanty and poorly reported safety data and have not provided evidence that can be used to determine a reliable risk profile for vitamin supplementation. Conservative interpretation of these results is warranted because vitamin D has been evaluated in a few small trials providing low‐ to very low‐quality evidence. We used a comprehensive, transparent, and pragmatic system for rating the quality of the evidence (i.e. the GRADE approach); according to this approach, any estimate of effect based on low‐ to very low‐quality evidence is very uncertain, and further research is likely to change the estimate. </p> </section> <h3 class="title" id="CD008422-sec-0089">Implications for research</h3> <section id="CD008422-sec-0089"> <p>Seven new trials are currently ongoing, and we are hopeful that their findings will contribute better evidence towards informing practice. Also, given the limited available evidence for patient‐important outcomes, such as disability and health‐related quality of life, and for the risk profile of vitamin D in patients with MS, new studies should include these outcomes in a standardised way. Additionally, these trials need to report high‐quality data on the benefit of vitamin D for patients with MS who are vitamin D deficient. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008422-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008422-sec-0008"></div> <div class="table" id="CD008422-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>[Vitamin D] compared with [Placebo] for [Multiple Sclerosis]</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> [People] with [Multiple Sclerosis] </p> <p><b>Settings:</b> [Centers providing care for PwMS] </p> <p><b>Intervention:</b> [Vitamin D] </p> <p><b>Comparison:</b> [Placebo] </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(no. of studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <td align="center" class="headercell" colspan="1" rowspan="3" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vitamin D</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annualised relapse rate (ARR) (number of relapses per patient per year)</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ARR in the control group ranged from 0.28 to 0.45.<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ARR in the intervention group was 0.05 lower (0.17 lower to 0.07 higher).</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,c</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Expanded Disability Status Scale (EDSS) score</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the control group ranged from 1.6 to 3.6 on a 0 to 10‐point scale (best to worst).<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention group was 0.25 lower (0.61 lower to 0.10 higher).</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,d</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI gadolinium‐enhancing T1 lesions</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of MRI lesions in the control group ranged from 0.1 to 0.36.<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of MRI lesions in the intervention group was 0.02 higher (0.45 lower to 0.48 higher). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,e</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: range 26 to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(10 events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> <p>(19 events)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk difference 0.01 (‐0.03 to 0.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>f,g</sup><br/>low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor adverse events</p> <p>Follow‐up: range 26 to 96 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> <p><sup>(130 events)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> <p>(143 events)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk difference 0.02 (‐0.02 to 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>g,h</sup><br/>low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>ARR: annualised relapse rate; CI: confidence interval; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; PwMS: person with multiple sclerosis; SAE: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Source of assumed baseline risk was the range of outcomes in control groups of the trials included in the meta‐analysis </p> <p><sup>b</sup>Downgraded by two levels because studies considered at serious or unclear risk of selection bias, performance and detection bias, and attrition bias </p> <p><sup>c</sup>Downgraded by one level for imprecision: studied in only 5/12 studies not reaching the optimal information size </p> <p><sup>d</sup>Downgraded by one level for imprecision: studied in only five small studies; the 95% CI of the pooled estimate includes both reduction and increase in disability score with vitamin D </p> <p><sup>e</sup>Downgraded by one level for imprecision: studied in only 2 studies; the 95% CI of the pooled estimate includes both reduction and increase in MRI lesions with vitamin D </p> <p><sup>f</sup>Downgraded by one level for serious risk of selective reporting: 4/12 studies did not report SAEs </p> <p><sup>g</sup>Downgraded by one level for imprecision </p> <p><sup>h</sup>Downgraded by one level for serious risk of selective reporting: minor adverse events were not collected through a systematic assessment </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008422-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-sec-0009">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-sec-0132">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD008422-sec-0009"></div> <p>Multiple sclerosis (MS) is an immune‐mediated disease of the central nervous system (CNS). Epidemiological studies have shown a characteristic geographical distribution of MS, with prevalence of the disease minimal at the Equator and increasing with North or South latitude (<a href="./references#CD008422-bbs2-0073" title="Simpson S Jr, BlizzardL , OtahalP , Van der MeiI , TaylorB . Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. Journal of Neurology, Neurosurgery, and Psychiatry2011;82(10):1132-41. [PMID: 21478203]">Simpson 2011</a>). This distribution would appear to be supported by circumstantial evidence implicating environmental factors of inadequate sunlight exposure and lack of vitamin D as predisposing factors for MS (<a href="./references#CD008422-bbs2-0035" title="FreedmanDM , DosemeciM , AlavanjaMC . Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occupational and Environmental Medicine2000;57(6):418-21. [PMID: 10810132]">Freedman 2000</a><a href="./references#CD008422-bbs2-0061" title="PonsonbyAL , LucasRM , van derMeiIA . UVR, vitamin D and three autoimmune diseases-multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochemistry and Photobiology2005;81(6):1267-75. [PMID: 15971932]">Ponsonby 2005</a>). A large volume of epidemiological and genetic studies have reported an association between low serum 25‐hydroxyvitamin D (25OHD) concentration and MS before and after the disease is triggered (<a href="./references#CD008422-bbs2-0058" title="Pierrot-DeseillignyC , SouberbielleJC . Vitamin D and multiple sclerosis: an update. Multiple Sclerosis and Related Disorders2017;14:35-45. [PMID: 28619429]">Pierrot‐Deseilligny 2017</a>). Low serum 25OHD levels (around 50 nmol/L) have been associated with an increased incidence of MS (<a href="./references#CD008422-bbs2-0034" title="EmbryAF , SnowdonLR , ViethR . Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Annals of Neurology2000;48(2):271-2. [PMID: 10939587]">Embry 2000</a>; <a href="./references#CD008422-bbs2-0054" title="MungerKL , LevinLI , HollisBW , HowardNS , AscherioA . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA2006;296(23):2832-8. [PMID: 17179460]">Munger 2006</a>). <a href="./references#CD008422-bbs2-0055" title="NielsenNM , MungerKL , Koch-HenriksenN , HougaardDM , MagyariM , JørgensenKT , et al. Neonatal vitamin D status and risk of multiple sclerosis: a population-based case-control study. Neurology2017;88(1):44–51. [PMID: 5200855]">Nielsen 2017</a> recently reported increased MS risk in newborns 15 to 30 years later, but a previous study provided no evidence of an association between neonatal vitamin D levels and disease risk (<a href="./references#CD008422-bbs2-0076" title="UedaP , RafatniaF , BäärnhielmM , et al. Neonatal vitamin D status and risk of multiple sclerosis. Annals of Neurology2014;76:338–46.">Ueda 2014</a>). <a href="./references#CD008422-bbs2-0053" title="MowryEM , KruppLB , MilazzoM , ChabasD , StroberJB , BelmanAL , et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Annals of Neurology2010;67(5):618-24. [PMID: 20437559]">Mowry 2010</a> and <a href="./references#CD008422-bbs2-0074" title="Soilu-HanninenM , AirasL , MononenI , HeikkilaA , ViljanenM , HanninenA . 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2005;11(3):266-71. [PMID: 15957505]">Soilu‐Hanninen 2005</a> reported a positive association between low 25OHD serum levels and early MS or clinically isolated syndrome (CIS). Observational studies on vitamin D supplementation in people with MS have shown that relapse rate was significantly reduced after supplementation was provided (<a href="./references#CD008422-bbs2-0058" title="Pierrot-DeseillignyC , SouberbielleJC . Vitamin D and multiple sclerosis: an update. Multiple Sclerosis and Related Disorders2017;14:35-45. [PMID: 28619429]">Pierrot‐Deseilligny 2017</a>). </p> <p>Many factors, such as season, ageing, latitude, adiposity, physical activity, smoking, and diet, can affect the association between 25OHD and health outcomes, but because of the large number of factors and inaccuracies in their measurement, observational studies might not be able to control fully for their confounding effects. Furthermore, the list of disorders associated with low 25OHD has continually increased. These issues have raised the question of whether low 25OHD might be the result, rather than the cause, of physiological disturbances involved in MS (<a href="./references#CD008422-bbs2-0026" title="AutierP , BoniolM , PizotC , MullieP . Vitamin D status and ill health: a systematic review. Lancet. Diabetes &amp; Endocrinology2014;2(1):76-89. [PMID: 24622671]">Autier 2014</a>). In the report on Dietary Reference Intakes for Calcium and Vitamin D issued by the Institute of Medicine (IOM) in 2011, the nature of the association between vitamin D levels and MS is judged as unclear and their relationship is considered associative rather than causative, that is, causation has not been proved (<a href="./references#CD008422-bbs2-0041" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.">IOM 2011</a>). </p> <section id="CD008422-sec-0010"> <h3 class="title" id="CD008422-sec-0010">Description of the condition</h3> <p>Multiple sclerosis is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the CNS. The disease manifests in a wide range of clinical presentations and with a variable clinical course. Typical clinical features include visual loss, double vision, motor weakness, spasticity, ataxia, tremor, sensory loss or impairment, sphincter dysfunction, and cognitive impairment. The course of the disease is so variable that some people become significantly disabled in a very short time, but others can live their entire lives with minimal or no disability. Complex interactions between genetic susceptibility, environmental risk factors, such as viral infections, and protective factors could occur at different times and could lead to development of MS. Vitamin D may serve as one of several protective factors. </p> <p>Researchers have reported many dysimmune processes involving T and B lymphocytes and several cytokines in MS (<a href="./references#CD008422-bbs2-0075" title="ThompsonAJ , BaranziniSE , GeurtsJ , HemmerB , CiccarelliO . Multiple sclerosis. Lancet2018;391:1622–36. [PMID: 29576504]">Thompson 2018</a>). Cytokines are small proteins important for cell signalling that have crucial functions in the development, differentiation, and regulation of immune cells. A vast majority of cytokines are produced by T‐helper (Th) cells. Interleukin (IL)‐1, tumour necrosis factor (TNF), gamma‐interferon (IFN‐γ), IL‐12, IL‐17, IL‐18, and granulocyte‐macrophage colony stimulating factor are pro‐inflammatory cytokines. IL‐4, IL‐10, IL‐13, IFN‐α, and transforming growth factor (TGF)‐β are anti‐inflammatory cytokines. Cytokines can also be classified by immunological response; type 1 cytokines (e.g. TNF‐α, IFN‐γ) enhance cellular immune responses, and type 2 cytokines (e.g. TGF‐β, IL‐4, IL‐10, IL‐13) favour antibody responses. Dysregulation of cytokine function causing an imbalance between pro‐inflammatory and immunosuppressive functions is postulated to have a central role in the development of autoimmune disease. Some cytokines, such as IL‐2, TNF, and interferons, are well known to promote immune and inflammatory responses, but they also serve crucial immunosuppressive functions (<a href="./references#CD008422-bbs2-0057" title="O'SheaJJ , MaA , LipskyP . Cytokines and autoimmunity. Nature Reviews. Immunology2002;2(1):37-45. [PMID: 11905836]">O'Shea 2002</a>). The matrix metalloproteinase‐9 (MMP9) protein has been found to be associated with numerous pathological processes and has been demonstrated to play an important role in the immunopathogenesis of MS (<a href="./references#CD008422-bbs2-0052" title="MirshafieyA , AsghariB , GhalamfarsaG , Jadidi-NiaraghF , AziziG . The significance of matrix metalloproteinases in the immunopathogenesis and treatment of multiple sclerosis. Sultan Qaboos University Medical Journal2014;14(1):e13-25. [PMID: 24516744]">Mirshafiey 2014</a>). </p> </section> <section id="CD008422-sec-0011"> <h3 class="title" id="CD008422-sec-0011">Description of the intervention</h3> <p>Vitamin D is a steroid hormone with pleiotropic and tissue‐specific effects due to wide expression of the nuclear vitamin D receptor in many different tissues and the many genes that are targeted by its actions. Vitamin D is a fat‐soluble vitamin that is naturally present in very few foods (e.g. fatty fish, fish liver oils), is added to others (e.g. milk), and is available as a dietary supplement. It is also produced endogenously when ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis. Vitamin D obtained through sun exposure, food, and supplements is biologically inert and must undergo two hydroxylations within the body for activation. The first occurs in the liver and converts vitamin D to 25OHD, also known as calcidiol. The second occurs primarily in the kidney and forms the physiologically active 1,25‐dihydroxyvitamin D, also known as calcitriol (<a href="./references#CD008422-bbs2-0040" title="Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academy Press, 2010.">IOM 2010</a>). Serum concentration of 25OHD is the best indicator of vitamin D status. It has a fairly long circulating half‐life of 15 days; it reflects vitamin D produced cutaneously and that obtained from food and supplements. 25OHD functions as a biomarker of exposure, but it is not clear to what extent 25OHD levels also serve as a biomarker of effect (i.e. relation to health status or outcomes). Serum 25OHD levels do not indicate the amount of vitamin D stored in body tissues (<a href="./references#CD008422-bbs2-0040" title="Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academy Press, 2010.">IOM 2010</a>). </p> <p>Considerable discussion surrounds the serum concentrations of 25OHD associated with deficiency (e.g. rickets), adequacy for bone health, and other diseases including autoimmune disorders (<a href="./references#CD008422-bbs2-0039" title="HolickMF , BinkleyNC , Bischoff-FerrariHA , GordonCM , HanleyDA , HeaneyRP , et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism2011;96:1911–30. [PMID: 21646368]">Holick 2011</a>; <a href="./references#CD008422-bbs2-0041" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.">IOM 2011</a>; <a href="./references#CD008422-bbs2-0066" title="RosenCJ , AbramsSA , AloiaJF , BrannonPM , ClintonSK , Durazo-ArvizuRA , et al. IOM committee members respond to Endocrine Society vitamin D guideline. The journal of clinical endocrinology and metabolism2012;97(4):1146-52. [PMID: 22442278]">Rosen 2012</a>). The committee of the Institute of Medicine concluded that persons are at risk of vitamin D deficiency at serum 25OHD concentrations &lt; 30 nmol/L (&lt; 12 ng/mL) (<a href="./references#CD008422-bbs2-0041" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.">IOM 2011</a>). Some are potentially at risk for inadequacy at levels ranging from 30 to 50 nmol/L (12 to 20 ng/mL). Levels ≥ 50 nmol/L (≥ 20 ng/mL) are sufficient for practically all people. The committee stated that 50 nmol/L is the serum 25OHD level that covers the needs of 97.5% of the population. Serum concentrations &gt; 125 nmol/L (&gt; 50 ng/mL) are associated with potential adverse effects such as hypercalcaemia, nephrolithiasis, and vascular calcifications (<a href="./references#CD008422-bbs2-0041" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.">IOM 2011</a>). </p> <p> <div class="table" id="CD008422-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serum 25‐hydroxyvitamin D (25OHD) concentrations and health<sup>a</sup> </b> </p> </td> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Serum concentrations<br/>of 25OHD</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Health status</b> </p> </th> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>nmol/L<sup>b</sup> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ng/mL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Associated with vitamin D deficiency, leading to rickets in infants and children and osteomalacia in adults </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 30</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generally considered inadequate for bone and overall health in healthy individuals</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 to 50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 to 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generally considered adequate for bone and overall health in healthy individuals</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 50</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emerging evidence links potential adverse effects to such high levels, particularly &gt; 150 nmol/L (&gt; 60 ng/mL) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 125</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> </tr> </tbody> </table> </div> </p> <p><sup>a</sup>Serum concentrations of 25OHD are reported in both nanomoles per litre (nmol/L) and nanograms per millilitre (ng/mL). <sup>b</sup>1 nmol/L = 0.4 ng/mL. </p> </section> <section id="CD008422-sec-0012"> <h3 class="title" id="CD008422-sec-0012">How the intervention might work</h3> <p>Vitamin D is important for normal growth and development of bone mediated through absorption of calcium from food and its ultimate deposition in bone. Apart from its involvement in bone metabolism, some reports suggest that vitamin D has other biologic mechanisms, including the action of limiting autoimmunity by suppressing inappropriate immune responses; regulating T‐helper cells, B lymphocytes, and dendritic cells (<a href="./references#CD008422-bbs2-0031" title="DannerOK , MatthewsLR , FrancisS , RaoVN , HarveyCP , TobinRP , et al. Vitamin D3 suppresses class II invariant chain peptide expression on activated B-lymphocytes: a plausible mechanism for downregulation of acute inflammatory conditions. Journal of Nutrition and Metablism2016;2016:4280876. [PMID: 27313879]">Danner 2016</a>; <a href="./references#CD008422-bbs2-0056" title="NiinoM , FukazawaT , KikuchiS , SasakiH . Therapeutic potential of vitamin D for multiple sclerosis. Current Medicinal Chemistry2008;15(5):499-505. [PMID: 18289005]">Niino 2008</a>); and reducing levels of inflammatory cytokines through control of gene expression (<a href="./references#CD008422-bbs2-0031" title="DannerOK , MatthewsLR , FrancisS , RaoVN , HarveyCP , TobinRP , et al. Vitamin D3 suppresses class II invariant chain peptide expression on activated B-lymphocytes: a plausible mechanism for downregulation of acute inflammatory conditions. Journal of Nutrition and Metablism2016;2016:4280876. [PMID: 27313879]">Danner 2016</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>). It has been reported that vitamin D is involved in immunomodulatory protective effects on the brain (<a href="./references#CD008422-bbs2-0072" title="ShiraziHA , RasouliJ , CiricB , RostamiA , ZhangGX . 1,25-dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation. Experimental and Molecular Pathology2015;98:240-5.">Shirazi 2015</a>), and that suboptimal levels of vitamin D may contribute to axonal inflammation and degeneration in patients with MS (<a href="./references#CD008422-bbs2-0069" title="SandbergL , BiströmM , SalzerJ , VågbergM , SvenningssonA , SundströmP . Vitamin D and axonal injury in multiple sclerosis. Multiple Sclerosis2016;22:1027-31.">Sandberg 2016</a>). Other trial authors have reported that vitamin D has a direct immunomodulatory effect on T cells of patients with early MS and is associated with improved regulatory T‐cell suppressive function (<a href="./references#CD008422-bbs2-0027" title="Bartosik-PsujekH , TabarkiewiczJ , PocinskaK , StelmasiakZ , RolinskiJ . Immunomodulatory effects of vitamin D on monocyte-derived dendritic cells in multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2010;16(12):1513-6. [PMID: 20739336]">Bartosik‐Psujek 2010</a>; <a href="./references#CD008422-bbs2-0048" title="LysandropoulosAP , JaquieryE , JilekS , PantaleoG , SchluepM , Du PasquierRA . Vitamin D has a direct immunomodulatory effect on CD8+ T cells of patients with early multiple sclerosis and healthy control subjects. Journal of Neuroimmunology2011;233(1-2):240-4. [PMID: 21186064]">Lysandropoulos 2011</a>; <a href="./references#CD008422-bbs2-0049" title="MahonBD , GordonSA , CruzJ , CosmanF , CantornaMT . Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. Journal of Neuroimmunology2003;134(1-2):128-32. [PMID: 12507780]">Mahon 2003</a>). The doses required to exert an immunoregulatory effect have been observed to be much higher than the recommended daily intake dose. </p> </section> <section id="CD008422-sec-0013"> <h3 class="title" id="CD008422-sec-0013">Why it is important to do this review</h3> <p>It has been proposed that vitamin D supplementation at moderate oral doses can already be undertaken in all types of people with MS, including pregnant women (<a href="./references#CD008422-bbs2-0078" title="WagnerCL , HollisBW , KotsaK , FakhouryH , KarrasSN . Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Reviews in Endocrine &amp; Metabolic Disorders2017;18(3):307-22. [PMID: 28214921]">Wagner 2017</a>), and it is recommended that in temperate countries, supplementation should never be stopped because there is no durable storage of this vitamin within the organism (<a href="./references#CD008422-bbs2-0058" title="Pierrot-DeseillignyC , SouberbielleJC . Vitamin D and multiple sclerosis: an update. Multiple Sclerosis and Related Disorders2017;14:35-45. [PMID: 28619429]">Pierrot‐Deseilligny 2017</a>). However, no consensus has been reached on the possible benefit of vitamin D for patients with MS. The IOM Committee concluded that evidence suggesting that vitamin D reduces risk of non‐skeletal chronic disease outcomes is inconsistent and inconclusive and does not meet the criteria for establishing cause‐and‐effect relationships (<a href="./references#CD008422-bbs2-0041" title="Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press, 2011.">IOM 2011</a>). This uncertainty regarding effects of vitamin D in MS is due to the limited number of randomised trials providing the most rigorous and valid research evidence on the relative benefit and safety of treatment. A summary of review results may help to clarify the stated uncertainty. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008422-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-sec-0014">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-sec-0137">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008422-sec-0014"></div> <p>To evaluate the benefit and safety of vitamin D supplementation for reducing disease activity in people with MS. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008422-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-sec-0015">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-sec-0138">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008422-sec-0015"></div> <section id="CD008422-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008422-sec-0017"> <h4 class="title">Types of studies</h4> <p>We searched for randomised controlled trials (RCTs) looking at treatment for MS. We excluded cross‐over studies because the effects if any of vitamin D are more likely to develop over a longer time, and therefore an appropriate washout period cannot be clearly defined. </p> </section> <section id="CD008422-sec-0018"> <h4 class="title">Types of participants</h4> <p>We sought participants 18 years of age or older with a diagnosis of MS according to the diagnostic criteria of Schumacker (<a href="./references#CD008422-bbs2-0070" title="SchumackerGA , BeebeG , KiblerRF , KurlandLT , KurtzkeJF , McDowellF , et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Sciences1965;122:552-68. [PMID: 14313512]">Schumacker 1965</a>), Poser (<a href="./references#CD008422-bbs2-0062" title="PoserCM , PatyDW , ScheinbergL , McDonaldWI , DavisFA , EbersGC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13(3):227-31. [PMID: 6847134]">Poser 1983</a>), or McDonald (<a href="./references#CD008422-bbs2-0050" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology2001;50(1):121-7. [PMID: 11456302]">McDonald 2001</a>; <a href="./references#CD008422-bbs2-0059" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840-6. [PMID: 16283615]'>Polman 2005</a>; <a href="./references#CD008422-bbs2-0060" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69:292–302.">Polman 2011</a>). We included all subgroups of MS (relapsing‐remitting (RRMS), secondary‐progressive, primary‐progressive, and progressive‐relapsing), regardless of sex of the individual, degree of disability, and disease duration. </p> </section> <section id="CD008422-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included all preparations of vitamin D at any dose, frequency, duration, or administration route. Vitamin D can be compared with placebo, routine care, or low dose of vitamin D. Vitamin D was administered as monotherapy or in combination with calcium. Concomitant interventions were allowed if they were used equally in all intervention groups in the trial. </p> </section> <section id="CD008422-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD008422-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008422-list-0001"> <li> <p>Mean number of relapses per patient per year or annualised relapse rate (ARR)</p> </li> <li> <p>Change in Expanded Disability Status Scale (EDSS) score (<a href="./references#CD008422-bbs2-0047" title="KurtzkeJF . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33(11):1444-52. [PMID: 6685237]">Kurtzke 1983</a>) </p> </li> <li> <p>Number of participants experiencing change in EDSS score (i.e. at least one point for EDSS &lt; 6.0 or 0.5 point for EDSS &gt; 5.5 over a period of six months) </p> </li> <li> <p>Mean change in magnetic resonance imaging (MRI) parameters of disease activity, including new lesions on T2‐weighted images, preexisting lesions enlarged on T2‐weighted images, or gadolinium‐enhancing lesions in T1‐weighted images </p> </li> <li> <p>Time to the first treated relapse</p> </li> <li> <p>Quality of life measured by validated generic or MS‐specific scales (e.g. MS Quality of Life (MSQOL‐54) (<a href="./references#CD008422-bbs2-0077" title="VickreyBG , HaysRD , HarooniR , MyersLW , EllisonGW . A health-related quality of life measure for multiple sclerosis. Quality of Life Research1995;4(3):187-206. [PMID: 7613530]">Vickrey 1995</a>); Functional Assessment of MS (FAMS) (<a href="./references#CD008422-bbs2-0030" title="CellaDF , DineenK , ArnasonB , RederA , WebsterKA , KarabatsosG , et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology1996;47(1):129-39. [PMID: 8710066]">Cella 1996</a>); RAYS Scale (<a href="./references#CD008422-bbs2-0068" title="RotsteinZ , BarakY , NoyS , AchironA . Quality of life in multiple sclerosis: development and validation of the 'RAYS' scale and comparison with the SF-36. International Journal for Quality in Health Care2000;12(6):511-7. [PMID: 11202605]">Rotstein 2000</a>)) </p> </li> <li> <p>Adverse events (AEs) as defined by study authors in the following groups:</p> <ul id="CD008422-list-0002"> <li> <p>Proportion of participants with at least one serious adverse event (SAE)</p> </li> <li> <p>Proportion of participants with minor AEs (or rate of AEs, i.e. number of AEs per person‐years) </p> </li> </ul> </li> </ul> </p> </section> <section id="CD008422-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008422-list-0003"> <li> <p>Number of participants requiring hospitalisation owing to progression of the disease</p> </li> <li> <p>Proportion of participants who remained relapse‐free</p> </li> <li> <p>Cognitive functions: memory, concentration measured by validated and disease‐specific scales (e.g. Brief Repeatable Battery of Neuropsychological Tests (BRBNT)) (<a href="./references#CD008422-bbs2-0064" title="RaoSM , LeoGJ , BernardinL , UnverzagtF . Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology1991;41(5):685-91. [PMID: 2027484]">Rao 1991</a>) </p> </li> <li> <p>Physical symptoms:</p> <ul id="CD008422-list-0004"> <li> <p>Fatigue measured by validated scales (e.g. Fatigue Severity Scale (FSS) (<a href="./references#CD008422-bbs2-0045" title="KruppLB , LaRoccaNG , Muir-NashJ , SteinbergAD . The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology1989;46(10):1121-3. [PMID: 2803071]">Krupp 1989</a>); MS‐specific FSS (MFSS) (<a href="./references#CD008422-bbs2-0071" title="SchwartzJE , JandorfL , KruppLB . The measurement of fatigue: a new instrument. Journal of Psychosomatic Research1993;37(7):753-62. [PMID: 8229906]">Schwartz 1993</a>); Modified Fatigue Impact Scale (MFIS); visual analogue scale (VAS) (<a href="./references#CD008422-bbs2-0046" title="KruppLB , CoylePK , DoscherC , MillerA , CrossAH , JandorfL , et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology1995;45(11):1956-61. [PMID: 7501140]">Krupp 1995</a>)) </p> </li> <li> <p>Spasticity or spasms measured by the Ashworth Scale (<a href="./references#CD008422-bbs2-0028" title="BohannonRW , SmithMB . Interrater reliability of a modified Ashworth scale of muscle spasticity. Physical Therapy1987;67(2):206-7. [PMID: 3809245]">Bohannon 1987</a>) </p> </li> <li> <p>Bladder function, bowel symptoms, self‐reported symptom count, or change in symptoms assessed by validated questionnaires </p> </li> </ul> </li> <li> <p>Psychological symptoms: profile of mood states (<a href="./references#CD008422-bbs2-0051" title="McNairDM , LorrM , DropplemanLF . Manual for the Profile of Mood States. San Diego, CA: Educational and Industrial Testing Service, 1981.">McNair 1981</a>); self‐efficacy (<a href="./references#CD008422-bbs2-0043" title="JohnstonM , WeinmanM , WrightS . Measures in Health Psychology: A User's Portfolio. Windsor: NFER-NELSON, 1995.">Johnston 1995</a>); self‐esteem (<a href="./references#CD008422-bbs2-0067" title="RosenbergM . Society and the Adolescent Self-Image. Princeton, NJ: Princeton University Press, 1965.">Rosenberg 1965</a>); change in psychological symptoms assessed by validated questionnaires (<a href="./references#CD008422-bbs2-0043" title="JohnstonM , WeinmanM , WrightS . Measures in Health Psychology: A User's Portfolio. Windsor: NFER-NELSON, 1995.">Johnston 1995</a>) </p> </li> <li> <p>Serum levels of 25‐hydroxyvitamin D (25OHD) and calcium</p> </li> <li> <p>Bone mineral density (BMD) changes during the study period</p> </li> <li> <p>Immunological outcomes:</p> <ul id="CD008422-list-0005"> <li> <p>Mean change in cytokine profile</p> </li> <li> <p>Mean change in T‐lymphocyte proliferation response</p> </li> <li> <p>Mean change in plasma metalloprotease‐9 activity</p> </li> </ul> </li> </ul> </p> <p>All outcomes were evaluated at six months (24/26 weeks), at 12 months (48/52 weeks), and annually thereafter. Other timing of outcome measurements was considered and evaluated separately. </p> <p>A glossary is available (<a href="#CD008422-tbl-0002">Table 1</a>). </p> <div class="table" id="CD008422-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrhythmia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any disturbance of the normal rhythmic beating of the heart</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A small protein released by cells that has a specific effect on interactions or communications between cells, or on the behaviour of cells. Cytokines include interleukins, lymphokines, and cell signal molecules, such as tumour necrosis factor, and the interferons, which trigger inflammation and respond to infection </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demyelination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Damage to the myelin sheath of neurons</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metalloproteases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteolytic enzymes whose catalytic mechanism involves a metal, important in many aspects of biology, ranging from cell proliferation, differentiation, and remodelling of the extracellular matrix (ECM) to vascularisation and cell migration </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nephrolithiasis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of forming stones in the kidney, or lower down in the urinary tract</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteoporosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thinning of the bones with reduction in bone mass due to depletion of calcium and bone proteins </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phytohaemagglutinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteins isolated from the bean. They are used mainly in the study of immune mechanisms and in cell culture </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD008422-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>This review is an update of a previously published review (<a href="./references#CD008422-bbs2-0080" title="JagannathVA , FedorowiczZ , AsokanGV , RobakEW , WhamondL . Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008422. [DOI: 10.1002/14651858.CD008422]">Jagannath 2010</a>). We conducted a systematic search with no restrictions to identify all relevant published and unpublished RCTs. We included trials published in any language. </p> <section id="CD008422-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched the Trials Register of the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group (2 October 2017), which, among other sources, contains the following. </p> <p> <ul id="CD008422-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; October 2017 to most recent issue). </p> </li> <li> <p>MEDLINE (PubMed) (1966 to 2 October 2017).</p> </li> <li> <p>Embase (Embase.com) (1974 to 2 October 2017).</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO host) (1981 to 2 October 2017). </p> </li> <li> <p>Latin American and Caribbean Health Science Information Database (LILACS) (Bireme) (1982 to 2 October 2017). </p> </li> <li> <p>ClinicalTrial.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> <p>Information on the Trial Register of the Review Group and details of search strategies used to identify trials can be found in the "Specialised Register" section within the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MS/frame.html" target="_blank">module</a>. </p> <p>We have listed in <a href="./appendices#CD008422-sec-0093">Appendix 1</a> the keywords used to search for studies for inclusion in this review. </p> </section> <section id="CD008422-sec-0025"> <h4 class="title">Searching other resources</h4> <p>In addition, we used the following methods.</p> <p> <ul id="CD008422-list-0007"> <li> <p>We screened the bibliographic references of identified studies or review articles to identify additional studies. </p> </li> <li> <p>We screened abstract books of the main MS meetings (European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), European Federation of Neurological Societies (EFNS), European Neurological Society (ENS), American Academy of Neurology (AAN), American Neurological Association (ANA)) from 1990 to 2017. </p> </li> <li> <p>We contacted authors of relevant trials or reviews and other MS consumer societies and experts. </p> </li> </ul> </p> </section> </section> <section id="CD008422-sec-0026"> <h3 class="title" id="CD008422-sec-0026">Data collection and analysis</h3> <section id="CD008422-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We used the search strategy described above to identify titles and abstracts of studies that might be relevant to the review. Two review authors (VJ and ZF) independently screened the titles and abstracts and discarded studies that were not applicable. We obtained full copies of all relevant and potentially relevant studies, those appearing to meet the inclusion criteria, and those for which data in the title and abstract were insufficient to allow a decision. The two review authors then independently assessed the full‐text papers and resolved disagreements on the eligibility of included studies through discussion and consensus, or through consultation with a third review author party (GVA). Review authors excluded all irrelevant records and noted details of studies and reasons for their exclusion in the <a href="./references#CD008422-sec-0109" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD008422-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (VJ and CDP) independently obtained and extracted data using a predetermined form designed for this purpose. If disagreement arose between the two review authors, we met to achieve consensus. If studies were reported in multiple publications, we extracted data from different publications and then combined them onto a single data extraction form, so no data were omitted. </p> <p>We recorded on the data extraction form the following characteristics of included studies. </p> <p> <ul id="CD008422-list-0008"> <li> <p>Methods.</p> </li> <li> <p>Participants.</p> </li> <li> <p>Interventions.</p> </li> <li> <p>Outcomes, including adverse events.</p> </li> <li> <p>Funding source for studies.</p> </li> </ul> </p> </section> <section id="CD008422-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (VJ and ZF) independently assessed the risk of bias of included studies using Cochrane criteria (<a href="./references#CD008422-bbs2-0032" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). We assessed the following items: adequacy of sequence generation and allocation concealment; adequacy of blinding of participants, personnel, and outcome assessors; completeness of outcome data; and no selective outcome reporting. Another potential risk of bias that we considered was follow‐up at six months or sooner because these trials measured outcomes that were too short‐term to be clinically relevant for patients with MS. We planned to resolve discrepancies in judgement through discussion with a third review author (GVA); however this proved unnecessary. We judged the overall risk of bias of each included study according to the following criteria. </p> <p> <ul id="CD008422-list-0009"> <li> <p>Low risk of bias (plausible bias unlikely to seriously alter the results) if all of the above criteria were met. </p> </li> <li> <p>Unclear risk of bias (plausible bias that raises some doubt about the results) if one or more items were assessed as unclear. </p> </li> <li> <p>High risk of bias (plausible bias that seriously weakens confidence in the results) if one or more items did not meet the above criteria. </p> </li> </ul> </p> </section> <section id="CD008422-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>For each pairwise comparison and each outcome at each time point, we expressed individual study results as rate difference for the ARR; mean difference (MD) for continuous outcomes (i.e. changes in EDSS score and number of MRI gadolinium‐enhancing T1 lesions); standardised MD (SMD) for HRQOL because included studies measured this outcome on different scales; and risk difference (RD) for serious adverse events and minor adverse events because some included studies reported no events in either group. We reported all measures together with their 95% confidence intervals (CIs). If we could not enter available data for analysis owing to missing values, we reported data in appropriate sections of the review and in the Additional tables. </p> </section> <section id="CD008422-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We included only studies using a parallel‐group design, so participants were randomised to intervention or control with subsequent analysis performed at the individual allocation level. We excluded cross‐over studies. Cluster and multi‐arm trials have not been carried out to evaluate vitamin D in MS. </p> </section> <section id="CD008422-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the principal investigator for <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> and were able to obtain missing data and to clarify some inconsistencies in the published article. Communication with the principal investigator of <a href="./references#CD008422-bbs2-0013" title="LakatosP , NagyZ , KissL , HorvathC , TakacsI , FoldesJ , et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Zeitschrift fur Rheumatologie2000;59(Suppl 1):48-52. [PMID: 10769437]">Lakatos 2000</a> revealed that only two participants with MS were included in the study, and separate data for them were unavailable. <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> did not provide data on baseline HRQOL score, and email communication did not help in obtaining those data. Imputation was used to address missing data for standard deviations when possible, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="http://training.cochrane.org/resource/revman-calculator" target="_blank">Revman calculator</a>). </p> </section> <section id="CD008422-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>Potential sources of heterogeneity included different participant baseline clinical characteristics, different vitamin D formulations, different doses, and different treatment durations. We examined the distribution of these characteristics in the included studies. We assessed for statistical heterogeneity by visually inspecting forest plots and by performing the Chi² test using an alpha of 0.05 for statistical significance, along with the I² statistic. I² values of 0% to 40% might not be important; 30% to 60% may indicate moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% may show considerable heterogeneity (<a href="./references#CD008422-bbs2-0032" title="DeeksJJ , HigginsJPT , Altman DG (editors). Chapter 9. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Deeks 2011</a>). </p> </section> <section id="CD008422-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we conducted a comprehensive search for eligible studies and remained alert to duplication of data. We assessed within‐study reporting bias and judged a study to be at low risk if all of the study’s prespecified primary outcomes were reported as outlined in the study protocol. We were not able to assess the possibility of reporting bias using a funnel plot, as we included fewer than 10 studies in all analyses. </p> </section> <section id="CD008422-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Pairwise meta‐analysis was feasible only for some outcome measures in the small number of included studies. We pooled data using a random‐effects model. We expressed dichotomous outcome results as RDs, continuous outcome results as MDs and SMDs, and count data as rate differences, together with 95% confidence intervals. We conducted pairwise meta‐analyses using Review Manager 5 software (<a href="./references#CD008422-bbs2-0065" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2017.">RevMan 2017</a>). </p> </section> <section id="CD008422-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out subgroup analyses based on age, gender, type of MS, country of residence (based on sunlight exposure), co‐intervention with disease‐modifying drugs, and serum 25OHD levels. We aimed to take any statistical heterogeneity into account when interpreting the results, especially if we noted any variation in the direction of effect. </p> </section> <section id="CD008422-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We considered risk of bias of included studies when interpreting evidence using the GRADE approach. </p> </section> <section id="CD008422-sec-0038"> <h4 class="title">'Summary of findings' table</h4> <p>We present the main results of this review in a 'Summary of findings' (SoF) table, as recommended by Cochrane. The SoF table provides an overall grading of the quality of evidence related to each outcome based on GRADEpro GDT (www.gradepro.org; <a href="./references#CD008422-bbs2-0037" title="GRADEpro GDT. Hamilton (ON): GRADE Working Group, McMaster University, 2015. Available at gradepro.org, Version accessed 8/5/18.">GRADEproGDT 2015</a>). We graded the quality of evidence as high, moderate, low, or very low upon considering within‐study risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias. Assumed baseline risks used in calculating absolute risks were based on the range of outcomes measured in comparison groups in the included studies. </p> <p>We present the following outcomes in the SoF.</p> <p> <ul id="CD008422-list-0010"> <li> <p>ARR.</p> </li> <li> <p>Change in EDSS score.</p> </li> <li> <p>New MRI gadolinium‐enhancing T1 lesions.</p> </li> <li> <p>Serious adverse events.</p> </li> <li> <p>Minor adverse events.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008422-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008422-sec-0039"></div> <section id="CD008422-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD008422-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD008422-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD008422-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008422-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We identified 386 citations through electronic searches conducted on 2 October 2017. We reviewed in detail 26 full‐text articles, which led to the inclusion of 20 articles of 11 unique studies. We found seven additional ongoing reports through searching <a href="http://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov</a> (see <a href="./references#CD008422-sec-0110" title="">Characteristics of ongoing studies</a>). </p> </section> <section id="CD008422-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD008422-sec-0108" title="">Characteristics of included studies</a>. </p> <p>In this update we included 11 new studies (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>); these were not included in the previous published version of the review (<a href="./references#CD008422-bbs2-0080" title="JagannathVA , FedorowiczZ , AsokanGV , RobakEW , WhamondL . Vitamin D for the management of multiple sclerosis. Cochrane Database of Systematic Reviews2010, Issue 12. Art. No: CD008422. [DOI: 10.1002/14651858.CD008422]">Jagannath 2010</a>). This update includes a total of 12 RCTs evaluating vitamin D in participants with MS. </p> <section id="CD008422-sec-0043"> <h5 class="title">Trial characteristics</h5> <p>All included trials used a parallel‐group design. Trials were conducted between 2006 and 2015. The earliest trial was published in 2010, and the most recent in 2016. Seven trials were not funded by industry. Trials were conducted in Iran (n = 4) (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>), Europe (n = 3) (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>), North America (n = 2) (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>), Israel (n = 2) (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>), and Australia (n = 1) (<a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). </p> </section> <section id="CD008422-sec-0044"> <h5 class="title">Participants</h5> <p>Overall studies included 933 participants; 464 were randomised to the vitamin D group and 469 to the comparator group. The number of participants in each trial ranged from 23 in <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> to 232 in <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> (median 56). All studies, except <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>, which evaluated pregnant women with RRMS, included participants of both genders with a relapsing‐remitting MS course, with age range between 18 and 60 years, most of whom were receiving ongoing immunomodulatory therapy. Of the 12 included trials, nine (75%) reported the baseline vitamin D status of participants based on serum 25‐hydroxyvitamin D levels. Participants in six trials had baseline 25‐hydroxyvitamin D levels at or above vitamin D adequacy (20 ng/mL) (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). Participants in the other three trials had baseline 25‐hydroxyvitamin D levels considered vitamin D insufficient (&lt; 20 ng/mL) (<a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>). Two trials reported baseline vitamin D status of participants as inclusion criteria only: <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a> and <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> included participants with 25‐hydroxyvitamin D₃ serum levels &lt; 85 ng/mL and &gt; 40 ng/mL, respectively. <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> did not report any data on the vitamin D status of participants. The main outcomes in these trials were relapse rate, disability worsening as measured by the EDSS, MRI lesions, quality of life, and adverse events. </p> </section> <section id="CD008422-sec-0045"> <h5 class="title">Experimental interventions</h5> <section id="CD008422-sec-0046"> <h6 class="title">Vitamin D₃</h6> <p>Five trials (with 93 participants) administered vitamin D as vitamin D₃. Four trials tested vitamin D₃ singly (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>), and one trial tested vitamin D₃ combined with calcium (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>). Four trials administered vitamin D₃ orally, and one trial administered it as an intramuscular injection (<a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>). Two trials gave vitamin D₃ daily (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>); the dose was 40,000 IU over 28 weeks, followed by 10,000 IU for 12 weeks, and further down‐titrated to 0 IU for 12 weeks in <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; and 4370 IU plus 800 IU over 52 weeks in <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>. <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a> treated participants with 50,000 IU of vitamin D₃ every five days for three months. <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a> treated pregnant women with 50,000 IU of vitamin D₃ once a week from 12 to 16 weeks' gestation until delivery. <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> gave 300,000 IU of vitamin D₃ by intramuscular injection once monthly for six months. </p> </section> <section id="CD008422-sec-0047"> <h6 class="title">Vitamin D₃ ‐ cholecalciferol</h6> <p>Four trials (with 409 participants) administered vitamin D as vitamin D₃ (cholecalciferol). Two trials tested vitamin D₃ singly (<a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>); one trial tested vitamin D₃ combined with interferon beta‐1a (Rebif) (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>); and one trial tested vitamin D₃ combined with calcium (<a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>). All trials administered vitamin D₃ orally. Two trials gave vitamin D₃ daily (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>); the dose was 6670 IU for four weeks followed by 14,007 IU for 44 weeks plus interferon beta‐1a (Rebif) 44 mcg three times a week in <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>, and 10,000 IU for six months in <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>. Two trials administered vitamin D₃ at intervals. <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> treated participants with 20,000 IU of vitamin D₃ per week for 96 weeks, and <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> gave vitamin D₃ supplementation of 20,000 IU once a week for one year. </p> </section> <section id="CD008422-sec-0048"> <h6 class="title">Vitamin D₃ ‐ alfacalcidol (1α‐hydroxyvitamin D₃)</h6> <p>One trial (with 158 participants) administered vitamin D orally as alfacalcidol at a dose of 1 μg daily for six months (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>). </p> </section> <section id="CD008422-sec-0049"> <h6 class="title">Vitamin D₂</h6> <p>One trial (with 23 participants) administered vitamin D₂ orally at a test dose of 6000 IU + 1000 IU daily for a one‐year period (<a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). </p> </section> <section id="CD008422-sec-0050"> <h6 class="title">Calcitriol ‐ 1,25‐dihydroxyvitamin D</h6> <p>One trial (with 50 participants) administered vitamin D orally as calcitriol at a test dose of 0.25 μg daily, increased to 0.5 μg (20 IU) after two weeks for one year (<a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>). </p> </section> </section> <section id="CD008422-sec-0051"> <h5 class="title">Comparator interventions</h5> <p>Six trials used placebo (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>); one trial used arachis oil (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>); and one provided routine care (<a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>). Four trials compared high versus low doses of vitamin D (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). </p> </section> <section id="CD008422-sec-0052"> <h5 class="title">Follow‐up</h5> <p>Length of follow‐up was three months in <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; six months in <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>, <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>, and <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>; eight months in <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; 11 months in <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; 12 months in <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>, <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>, <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>, and <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; and 22 months in <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>. <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a> included pregnant women from 12 to 16 weeks' gestation until delivery and six months after delivery. </p> </section> </section> <section id="CD008422-sec-0053"> <h4 class="title">Ongoing studies</h4> <p>We identified seven ongoing RCTs (<a href="./references#CD008422-bbs2-0019" title="NCT01198132. A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly [A Multicentre, Randomised, Double-blind, Placebo-controlled Study of the Efficacy of Supplementary Treatment With Cholecalciferol (Vitamin D3) in Patients With Relapsing-Multiple Sclerosis (RMS) Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly]. https://clinicaltrials.gov/ct2/show/record/NCT01198132, 8 September 2010. ">NCT01198132</a>; <a href="./references#CD008422-bbs2-0020" title="NCT01440062. Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS) [Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis]. https://clinicaltrials.gov/ct2/show/record/NCT01440062, 19 September 2011. ">NCT01440062</a>; <a href="./references#CD008422-bbs2-0021" title="NCT01490502. Vitamin D Supplementation in Multiple Sclerosis [A Randomized Controlled Trial of Vitamin D Supplementation in Multiple Sclerosis]. https://clinicaltrials.gov/ct2/show/record/NCT01490502, 6 December 2011. ">NCT01490502</a>; <a href="./references#CD008422-bbs2-0022" title="NCT01753375. Role of Vitamin D on the Relapse Rate of Multiple Sclerosis [Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis]. https://clinicaltrials.gov/ct2/show/record/NCT01753375, 17 December 2012. ">NCT01753375</a>; <a href="./references#CD008422-bbs2-0023" title="NCT01768039. Vitamine D in Multiple Sclerosis [Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis]. https://clinicaltrials.gov/ct2/show/record/NCT01768039, 11 January 2013. ">NCT01768039</a>; <a href="./references#CD008422-bbs2-0024" title="NCT01817166. Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome [Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years]. https://clinicaltrials.gov/ct2/show/record/NCT01817166, 20 March 2010. ">NCT01817166</a>; <a href="./references#CD008422-bbs2-0025" title="O'ConnellK , KellyS , KinsellaK , JordanS , KennyO , MurphyD , et al. Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double-blind placebo-controlled trial. Trials2013;(14):272. [DOI: 10.1186/1745-6215-14-272]">O'Connell 2013</a>). We will include these studies in a future update of this review. The <a href="./references#CD008422-sec-0110" title="">Characteristics of ongoing studies</a> table provides details on the characteristics of these seven studies. </p> </section> <section id="CD008422-sec-0054"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD008422-sec-0109" title="">Characteristics of excluded studies</a>. </p> <p>We excluded six studies. Four were not randomised studies (<a href="./references#CD008422-bbs2-0014" title="NajafipoorA , RoghanianR , Zarkesh-EsfahaniSH , BouzariM , EtemadifarM . The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients. Cellular Immunology2015;294(1):9-12. ">Najafipoor 2015</a>; <a href="./references#CD008422-bbs2-0015" title="Pierrot-DeseillignyC , Rivaud-PéchouxS , ClersonP , dePazR , SouberbielleJC . Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Therapeutic Advances in Neurological Disorders2012;5(4):187–98. [PMID: 22783368]">Pierrot‐Deseilligny 2012</a>; <a href="./references#CD008422-bbs2-0017" title="Shirvani-FarsaniZ , BehmaneshM , MohammadiSM , Naser MoghadasiA . Vitamin D levels in multiple sclerosis patients: association with TGF-beta2, TGF-betaRI, and TGF-betaRII expression. Life Sciences2015;1(134):63-7. ">Shirvani‐Farsani 2015</a>; <a href="./references#CD008422-bbs2-0018" title="WingerchukDM , LesauxJ , RiceGP , KremenchutzkyM , EbersGC . A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2005;76(9):1294-6. [PMID: 16107372]">Wingerchuk 2005</a>). One study did not include the appropriate population; participants had received a diagnosis of systemic lupus erythematosus, MS, rheumatoid arthritis, or asthma bronchiale; and communication with the study author by email revealed that only two participants in the study had MS, and separate data for these participants were not available (<a href="./references#CD008422-bbs2-0013" title="LakatosP , NagyZ , KissL , HorvathC , TakacsI , FoldesJ , et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Zeitschrift fur Rheumatologie2000;59(Suppl 1):48-52. [PMID: 10769437]">Lakatos 2000</a>). <a href="./references#CD008422-bbs2-0016" title="RøsjøE , LossiusA , AbdelmagidN , LindstromJC , KampmanMT , JorgensenL , et al. Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2017;23(3):395-402. ">Røsjø 2017</a>, which reported on an included trial (<a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>), provided only data on antibodies against Epstein–Barr virus, which are outcome measures not included in the review. </p> </section> </section> <section id="CD008422-sec-0055"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarised risk of bias in <a href="#CD008422-fig-0002">Figure 2</a> and <a href="#CD008422-fig-0003">Figure 3</a>. In the light of our predefined criteria (<a href="#CD008422-sec-0029">Assessment of risk of bias in included studies</a>), we judged that five out of 12 (42%) trials were at unclear risk of bias (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>), and the remaining seven (58%) trials had high risk of bias for one or more of the components assessed. </p> <div class="figure" id="CD008422-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008422-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008422-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008422-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD008422-sec-0056"> <h4 class="title">Allocation</h4> <p>Generation of the allocation sequence was adequate in four trials (<a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>), but it was inadequate in two trials (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>). The remaining six trials were described as randomised, but study authors did not describe the method used for sequence generation. We judged the method used for allocation concealment to be adequate in two trials (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>), inadequate in four trials (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>), and unclear in six trials (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). </p> </section> <section id="CD008422-sec-0057"> <h4 class="title">Blinding</h4> <p>Seven trials adequately described the method of blinding. In three trials the method of blinding was unclear (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>), and two trials were not blinded (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>). </p> </section> <section id="CD008422-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>Five trials did not adequately address incomplete data (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). For two trials (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>), information was insufficient to allow assessment of attrition bias. The remaining five trials adequately addressed incomplete outcome data. </p> </section> <section id="CD008422-sec-0059"> <h4 class="title">Selective reporting</h4> <p>We judged eight trials to be at unclear risk of reporting bias because study authors made no mention of an a priori protocol or clinical trial registration information. We judged the remaining four trials to be at low risk of bias for this domain (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>). </p> </section> <section id="CD008422-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Seven included trials appear to be free of other components that could put them at risk of bias. Four trials reported follow‐up of six months or less and we considered them to be at high risk of bias (<a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>). One trial provided insufficient information to allow assessment of other potential sources of bias (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>). </p> </section> </section> <section id="CD008422-sec-0061"> <h3 class="title" id="CD008422-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD008422-tbl-0001"><b>Summary of findings 1</b> Summary of findings</a> </p> <p><a href="./full#CD008422-tbl-0001">summary of findings Table 1</a> provides overall estimates of effects of vitamin D compared with placebo, along with quality of available evidence for benefit outcomes (annualised relapse rate and EDSS scores over 52 weeks, the number of MRI gadolinium‐enhancing T1 lesions over 26 weeks), obtained through pairwise meta‐analyses. </p> <section id="CD008422-sec-0062"> <h4 class="title">Primary outcomes</h4> <section id="CD008422-sec-0063"> <h5 class="title">Mean number of relapses per patient per year or annualised relapse rate (ARR)</h5> <p>See <a href="./full#CD008422-tbl-0001">summary of findings Table 1</a>, <a href="./references#CD008422-fig-0004" title="">Analysis 1.1</a>, and <a href="#CD008422-tbl-0003">Table 2</a>. </p> <div class="table" id="CD008422-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Annualised relapse rate (ARR)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Control group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 to 0.24<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.02 to 0.18*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>95% confidence interval </p> </div> </div> <p>Five studies involving 417 participants (45% of those included in this review) reported the annualised relapse rate (ARR) at 52 weeks (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>). Researchers found that vitamin D did not reduce the number of relapses (rate difference ‐0.05, 95% confidence interval (CI) ‐0.17 to 0.07). The heterogeneity I² for this meta‐analysis was 38%, which we considered low. Using GRADE criteria, we considered the evidence to be of very low certainty, downgrading by two levels because we judged the evidence to be at serious risk of suffering from selection bias, performance bias, and attrition bias. We downgraded certainty an additional level for imprecision. A sixth study involving 68 participants (7% of those included in this review) measured ARR at 96 weeks and found no differences between groups (rate difference 0.06, 95% CI ‐0.08 to 0.20) (<a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>). Two studies reported ARR, but the data were unsuitable for data extraction. <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a> reported the mean number of relapses in pregnant women as 0.0 (standard deviation (SD) 0) (with six participants) in the intervention group and 0.4 (SD 0.5) (with nine participants) in the comparison group after six months of delivery. <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> reported that the proportion of participants free of relapse was significantly higher in the alfacalcidol treatment arm than in the comparison arm (89.5% vs 67.1%, respectively; P = 0.007). Reduction in relapses with alfacalcidol became significant at four months of treatment and was sustained at six months (end of study). This beneficial effect was diminished at the follow‐up visit two months after alfacalcidol discontinuation. </p> </section> <section id="CD008422-sec-0064"> <h5 class="title">Change in the Expanded Disability Status Scale (EDSS) score</h5> <p>See <a href="./full#CD008422-tbl-0001">summary of findings Table 1</a> and <a href="./references#CD008422-fig-0005" title="">Analysis 1.2</a>. </p> <p>Five studies involving 221 participants (24% of those included in this review) reported the EDSS score change at 52 weeks (<a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>). These studies found no differences in EDSS change between groups (mean difference (MD) ‐0.25, 95% CI ‐0.61 to 0.10). The heterogeneity I² for this meta‐analysis was 35%, which we considered low. We downgraded the certainty of the evidence by two levels because we judged the evidence to be at serious risk of suffering from selection bias, performance bias, and attrition bias. We downgraded certainty an additional level for imprecision, as the confidence interval of the pooled effect included both reduction and increase in disability score with vitamin D. <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> and <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> (217 participants) reported EDSS score at 26 weeks and found no differences between groups (MD ‐0.10, 95% CI ‐0.37 to 0.17). <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> (68 participants) reported EDSS score at 96 weeks and found no differences between comparison groups (MD 0.35, 95% CI ‐0.21 to 0.91). Data from <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> (20 participants) were unsuitable for data extraction because the article reported median (interquartile ratio (IQR)) EDSS scores at six months. This study found that treatment with high‐dose vitamin D₂ was marginally associated with higher EDSS scores at the end of the study (P = 0.051). </p> </section> <section id="CD008422-sec-0065"> <h5 class="title">Number of participants experiencing a change/reduction in the Expanded Disability Status Scale (EDSS) score </h5> <p>No trials reported this outcome.</p> </section> <section id="CD008422-sec-0066"> <h5 class="title">Number of MRI gadolinium‐enhancing T1 lesions</h5> <p>See <a href="./full#CD008422-tbl-0001">summary of findings Table 1</a> and <a href="./references#CD008422-fig-0006" title="">Analysis 1.3</a>. </p> <p>Two studies involving 82 participants with multiple sclerosis (9% of the participants in this review) reported the number of MRI gadolinium‐enhancing T1 lesions over 26 weeks (<a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>; <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a>), and two studies with 256 participants (27% of those included in this review) reported this number over 52 weeks (<a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>). Mean differences were ‐0.09 (95% CI ‐0.52 to 0.34) and 0.02 (95% CI ‐0.45 to 0.48), respectively, at 26 and 52 weeks. Values for heterogeneity (I²) for timing of each outcome seem to show no evidence of heterogeneity. </p> </section> <section id="CD008422-sec-0067"> <h5 class="title">Time to the first treated relapse</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD008422-sec-0068"> <h5 class="title">Quality of life (QOL) (validated and specific scales, i.e. MSQOL‐54, RAYS, FAMS)</h5> <p>See <a href="./references#CD008422-fig-0007" title="">Analysis 1.4</a>. </p> <p>Three studies reported QOL outcomes using three different validated scales (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>). <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> (158 participants; 17% of those included in this review) used the RAYS Scale and reported that vitamin D led to improvement in the psychological and social components of RAYS but had no effects on the physical components. <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a> (94 participants; 10% of those included in this review) measured physical, mental, and sexual satisfaction and health change components of the MSQOL and found no difference in any component between comparison groups. <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> (45 participants; 5%) used the FAMS questionnaire, a functional assessment of MS, and found no differences between groups. </p> </section> <section id="CD008422-sec-0069"> <h5 class="title">Serious adverse events (SAEs)</h5> <p>See <a href="./full#CD008422-tbl-0001">summary of findings Table 1</a>, <a href="./references#CD008422-fig-0008" title="">Analysis 1.5</a>, and <a href="#CD008422-tbl-0004">Table 3</a>. </p> <div class="table" id="CD008422-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events (SAEs)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VigantOL oil plus interferon beta‐1a (Rebif)</p> <p>Number of participants with at least 1 SAE out of 113 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo plus interferon beta‐1a (Rebif)</p> <p>Number of participants with at least 1 SAE out of 116 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least one SAE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/113 (15.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/116 (6.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac disorders/failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disorders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/113 (2.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cellulitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyelonephritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overdose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/113 (7.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/116 (5.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ovarian cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Syncope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menorrhagia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uterine polyp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Events were not collected via systematic assessment.</p> </div> </div> <p>Eight studies involving 621 participants (67% of those included in this review) reported SAEs (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>). Combined analysis of the results of these eight trials yielded a combined risk difference of 0.01 (95% CI ‐0.03 to 0.04). The heterogeneity I² for this meta‐analysis was 35%, which we considered low. Using GRADE criteria, we downgraded the certainty of the evidence by two levels from high to low, in part because of imprecision, in part because of risk of selective reporting. Four of 12 studies did not report SAEs, and the absence of a protocol did not allow us to assess whether measurement of SAEs may have been planned but not reported. None of the participants in six trials experienced SAEs (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>). In the <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> trial, 18 (16%) of the 113 participants in the intervention group and eight (7%) of the 116 participants in the placebo group experienced SAEs, and the risk difference in this trial was 0.09 (95% CI 0.01 to 0.17), suggesting that high‐dose vitamin D₃ supplementation is associated with significant serious adverse events (<a href="#CD008422-tbl-0004">Table 3</a>). <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> reported that one participant with erysipelas in the vitamin D group required intravenous antibiotics, as did two participants with elective hip surgery and elbow fracture in the placebo group. None of the eight studies that reported SAEs observed nephrolithiasis. </p> </section> <section id="CD008422-sec-0070"> <h5 class="title">Minor adverse events</h5> <p>See <a href="./full#CD008422-tbl-0001">summary of findings Table 1</a> and <a href="./references#CD008422-fig-0009" title="">Analysis 1.6</a> </p> <p>Eight studies involving 701 participants (75% of those included in this review) reported minor adverse events (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>; <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a>; <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a>; <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a>). Combined analysis of the results of these eight trials yielded a combined risk difference of 0.02 (95% CI ‐0.02 to 0.06). The heterogeneity I² for this meta‐analysis was 20%, which we considered low. Using GRADE criteria, we judged the certainty of the evidence as low. We downgraded by one level for risk of selective reporting because minor adverse events were not collected via a systematic assessment. We downgraded an additional level for imprecision. <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> and <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> reported no adverse events with vitamin D and no withdrawals due to adverse events, suggesting that the intervention was tolerated well and resulted in no clinical or biochemical adverse effects in either intervention group. <a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> reported adverse events in both groups that included diarrhoea, constipation, fever, fatigue, headache, and dyspepsia (12/25 in the placebo group vs 18/25 in the vitamin D group). <a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> reported adverse events with no significant differences between groups. Study authors reported no hypercalcaemia or other biochemical abnormalities in the vitamin D group and reported minor adverse events such as lack of induction of the myxovirus resistance protein A, fever, and diarrhoea in 10/30 in the placebo group versus 10/32 in the vitamin D group. <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> reported nausea in three participants (1/21 in the low‐vitamin D group vs 2/19 in the high‐vitamin D group) who withdrew from the study, and elevated serum calcium levels above the safe level of 10 mg/dL in one patient in the high‐vitamin D group who had to discontinue treatment, and in one patient with hypercalciuria in each group, all of whom were shifted to an alternate‐day treatment regimen. <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a><a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>, and <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> reported no adverse events. </p> </section> </section> <section id="CD008422-sec-0071"> <h4 class="title">Secondary outcomes  </h4> <section id="CD008422-sec-0072"> <h5 class="title">Number of participants requiring hospitalisation owing to disease progression</h5> <p>No trials reported on this outcome.</p> </section> <section id="CD008422-sec-0073"> <h5 class="title">Proportion of relapse‐free participants</h5> <p><a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> found that alfacalcidol increased the proportion of relapse‐free participants compared with placebo (89% vs 67%, respectively; P = 0.007) at six months. <a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> reported four relapses with high‐dose vitamin D₂ and none with low‐dose vitamin D₂ (P = 0.04). </p> </section> <section id="CD008422-sec-0074"> <h5 class="title">Cognitive functions (memory, concentration)</h5> <p>No trials reported these outcomes.</p> </section> <section id="CD008422-sec-0075"> <h5 class="title">Physical symptoms</h5> <p>Two studies reported fatigue using two different validated scales (<a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>; <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>). <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> used the Fatigue Impact Scale (FIS), and <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> used the Fatigue Severity Scale (FSS). Results were different between the two studies. In <a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a>, the standardised mean difference (SMD) was ‐0.62 (95% CI ‐0.94 to ‐0.30), suggesting that alfacalcidol reduced fatigue compared with placebo at 26 weeks. <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> found that cholecalciferol did not reduce fatigue at 96 weeks (SMD 0.13, 95% CI ‐0.34 to 0.61). </p> </section> <section id="CD008422-sec-0076"> <h5 class="title">Psychological symptoms</h5> <p>No trials reported this outcome.</p> </section> <section id="CD008422-sec-0077"> <h5 class="title">Serum levels of 25‐hydroxyvitamin D (25OHD)</h5> <p>In <a href="#CD008422-tbl-0005">Table 4</a>, we report 25OHD levels at baseline and during the intervention along with the range of vitamin D dose supplementation provided in the included trials. Three of the 12 included trials evaluated patients with mean 25OHD concentration less than 50 nmol/L at baseline and provided supplementation of 50 μg or more per day (<a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a>; <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a>; <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a>). The other trials reported mean 25OHD concentrations above 50 nmol/L at baseline among included participants. </p> <div class="table" id="CD008422-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">25OHD levels at baseline and during the intervention with the range of vitamin D dose supplementation in the included trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study and country</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration (months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants included in trials (n)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of vitamin D₃ dose (µg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline 25OHD in intervention groups (nmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25OHD during the intervention (nmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of clinical benefit outcomes assessed by trials (n)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of clinical benefit outcomes with significant improvement (n)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> Israel </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 every 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>70.56 ± 72.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR) <br/>211.33 ± 107.00 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per day over 6 months followed by 250 per day for 3 months, then down‐titrated to 0 for the last 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>73 (38 to 146)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>38.25 ± 7.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>84.25 ± 38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.25 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>48.2 ± 13.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>122.6 ± 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> <p>(Muris 2016)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 per day for 4 weeks increased to 350 per day for 44 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>60 (38 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>231 (162 to 250)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (95% CI)</p> <p>55.56 (46.87 to 64.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (95% CI)</p> <p>123.17 (112.99 to 133.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7500 every month as intramuscular injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcitriol 0.25 per day increased to 0.5 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>54 (19 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>110 (67 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>67 (22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>166 (46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D<b>₂</b> 150 per day </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>59 (47 to 61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>120 (89 to 170)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>25OHD: 25‐hydroxyvitamin D</p> <p>CI: confidence interval</p> <p>IQR: interquartile ratio</p> <p>NR: not reported</p> <p>SD: standard deviation</p> </div> </div> </section> <section id="CD008422-sec-0078"> <h5 class="title">Bone mineral density (BMD) changes during the study period</h5> <p>Steffensen 2011 (sub‐reference under <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>) reported on BMD changes at the hip, spine, and radius between baseline and end of study. At the hip, BMD decreased by 1.4% in the placebo group (95% CI ‐2.3 to ‐0.4; P = 0.006) and by 0.7% in the treatment group (95% CI ‐1.6 to 0.2; P = 0.118). Both groups showed bone loss in weight‐bearing bones among people with MS. At the spine, BMD decreased by 0.1% (95% CI ‐1.3 to 1.2) and by 0.3% (95% CI ‐1.2 to 0.7), and at the radius, data show an increase of 1.3% (95% CI ‐0.7 to 3.3) and 2.3% (95% CI 0.3 to 4.2) after 96 weeks, indicating no change in bone loss due to the intervention. </p> </section> <section id="CD008422-sec-0079"> <h5 class="title">Cytokine profile, T‐lymphocyte proliferation response, and plasma metalloprotease‐9 activity </h5> <p>Ashtari 2015 and Toghianifar 2015 (sub‐references under <a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a>) found no differences in anti‐inflammatory IL‐10 levels nor in pro‐inflammatory IL‐17 levels between vitamin D₃ and placebo groups. <a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> compared T‐cell proliferative responses at first and final visits, 52 weeks apart, for all participants. The number of positive proliferative responses to antigenic stimulation decreased significantly in the treatment group during the trial (sign test; P = 0.002), with no change reported among controls. Data show no consistent patterns of change in cytokine levels between comparison groups. <a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> reported that IL‐17 levels were significantly increased in the low‐dose group, while participants receiving high‐dose vitamin D had a heterogeneous IL‐17 response (<a href="#CD008422-tbl-0006">Table 5</a>). <a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> found that after six months, levels of peripheral blood mononuclear cell proliferation in the vitamin D treatment group were significantly lower than in the control group, and that levels of transforming growth factor‐beta and of anti‐inflammatory IL‐10 in the vitamin D treatment group were significantly higher than in the control group (<a href="#CD008422-tbl-0007">Table 6</a>). Røsjø 2015 (sub‐reference under <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>) reported no significant differences between vitamin D and placebo groups for any of the inflammation markers, including plasma metalloprotease‐9 activity (<a href="#CD008422-tbl-0008">Table 7</a>). Muris 2016 (sub‐reference under <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>) measured levels of various cytokines to assess functional effects of vitamin D₃ on the T‐helper cell compartment. T cells within peripheral blood mononuclear cells were activated in vitro, and anti‐CD3 and cytokine levels were measured. Proportions of T‐helper subsets were not affected by vitamin D₃, except the proportion of IL‐4 T‐helper cells, which was decreased in the placebo group but not in the vitamin D₃ group. T‐cell cytokine secretion increased most notably for IL‐5 in the placebo group but not in the vitamin D₃ group. This study found that vitamin D₃ supplementation prevented an imbalance in cytokine production upon T‐cell activation (<a href="#CD008422-tbl-0009">Table 8</a>). <a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> found that high‐dose cholecalciferol supplementation exhibited in vivo immunomodulatory effects, which included reduced production of IL‐17 by CD41 T cells and decreased proportions of effector memory CD41 T cells, with a concomitant increase in central memory CD41 T cells and naive CD41 T cells (<a href="#CD008422-tbl-0010">Table 9</a>). </p> <div class="table" id="CD008422-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ ‐ low dose (21 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ ‐ high dose (24 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months of treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐<i>γ</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (1.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (1.3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐7 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.01 (3.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.14 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (6.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (6.7)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Cytokine levels are given as means (SD).</p> <p>IFN‐<i>γ:</i> interferon gamma </p> <p>IL‐7: interleukin‐7</p> <p>IL‐10: interleukin‐10</p> <p>pg/mL: picogram/millilitre</p> </div> </div> <div class="table" id="CD008422-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ (26 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo (33 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐<i>γ</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2530 (230)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2250 (143)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 (98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980 (120)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3600 (430)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4950 (530)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3430 (312)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3750 (325)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TGF‐<i>β</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (2.4)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (2)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Cytokine levels are given as means (SD).</p> <p><sup>a</sup>P value = 0.0001. </p> <p>IFN‐<i>γ:</i> interferon gamma </p> <p>IL‐10: interleukin‐10</p> <p>pg/mL: picogram/millilitre</p> <p>TGF‐<i>β:</i> tumour growth factor beta </p> </div> </div> <div class="table" id="CD008422-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Serum inflammatory marker levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Mean change in inflammation markers from baseline to end of study in the vitamin D group and the placebo group </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Røsjø 2015</p> <p>(sub‐reference under <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D₃ (36 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (32 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group difference</p> <p>crude change (P value)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALCAM (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5 (0.130)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CCL21 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (129)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (115)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (0.284)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CXCL16 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (224)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (242)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5 (0.763)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐1Ra (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (478)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10 (115)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (0.175)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMP‐9 (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 (464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (529)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (0.719)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPG (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (307)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐33 (228)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (0.390)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPN (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.0 (2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.252)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTX3 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐39 (566)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐95 (458)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (0.638)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sFRP3 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3775)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 (736)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐115 (0.995)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sTND‐r1 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 (164)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (139)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (0.589)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TGF‐β1 (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.1 (0.717)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Levels of markers are given as mean change (SD); P value calculated by the Mann–Whitney test. </p> <p>ALCAM: activated leucocyte cell adhesion molecule</p> <p>CCL21: chemokine (C–C motif) ligand 21</p> <p>CXCL16: chemokine (C–X–C motif) ligand 16</p> <p>IL‐1Ra: interleukin‐1 receptor antagonist</p> <p>MMP‐9: matrix metalloproteinase‐9</p> <p>ng/mL: nanogram/millilitre</p> <p>OPG: osteoprotegerin</p> <p>OPN: osteopontin</p> <p>pg/mL: picogram/millilitre</p> <p>PTX3: pentraxin 3</p> <p>sFRP3: secreted frizzled‐related protein 3</p> <p>sTND‐r1: soluble tumour necrosis factor receptor 1</p> <p>TGF‐β1: transforming growth factor beta 1</p> </div> </div> <div class="table" id="CD008422-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muris 2016</p> <p>(sub‐reference under <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Effect of vitamin D₃ supplementation on cytokine production</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marker</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Placebo plus IFN beta (Rebif) (23 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Vitamin D₃ plus IFN‐beta (Rebif) (30 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Log ratio</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713.9 (397.5 to 1319.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>806.1 (391.7 to 1618.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>913.8 (646.3 to 1431.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>934.3 (548.1 to 1388.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐4 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.6 to 3.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8 (0.7 to 2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.8 to 4.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.8 to 2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐5 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.4 (22.5 to 171.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105.5 (52.5 to 335.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9(45.4 to 134.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6 (45.8 to 145.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1451.4 (898.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1365.4 (877.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1673.1 (846.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1562.4 (798.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐17 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1112.2 (540.6 to 1713.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1181.0 (683.4 to 2408.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>825.0 (456.4 to 2311.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233.1 (582.5 to 2504.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐22 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261.3 (128.6 to 302.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.1 (58.0 to 434.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181.8 (123.3 to 502.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234.3 (116.7 to 390.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM‐CSF (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>674.5 (391.3 to 903.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843.9 (406.3 to 1456.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737.4 (474.6 to 1054.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765.7 (495.7 to 1038.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499.3 (196.1 to 800.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765.6 (479.7 to 1080.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>676.1 (434.7 to 1022.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>897.2 (428.2 to 1394.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAP (pg/mL))</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543.1 (410.2 to 674.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894.6 (689.1 to 1097.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762.0 (527.0 to 907.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>753.9 (549.8 to 942.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ/IL‐5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (3.6 to 50.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (11.9 to 35.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (2.4 to 28.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1 (5.7 to 34.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Cytokine production in supernatant of anti‐CD3 stimulated peripheral blood mononuclear cells in participants included in this review. Mean and standard deviation (paired t test) or median and range (Wilcoxon Rank test) and P value of <sup>10</sup>log ratio week 48/week 0 (t test or Mann Whitney U test). </p> <p>GM‐CSF: granulocyte‐macrophage colony–stimulating factor</p> <p>IFN‐γ: interferon‐gamma</p> <p>IL: interleukin</p> <p>LAP: latency‐associated peptide</p> <p>pg/mL: picogram/millilitre</p> <p>TNF‐α: tumour necrosis factor‐α</p> </div> </div> <div class="table" id="CD008422-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Immune cell subtype changes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Immune cell subtype changes during the study, mean difference, % (95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of change during study between<br/>groups, mean difference, % (95% CI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐17<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.68 (0.13 to 5.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.039</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.32 (‐2.89 to 13.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ<sup>+</sup> IL‐17<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (‐0.66 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effector memory CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.24 (‐2.19 to 18.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central memory CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.08 (‐19.23 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive CD4<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.99 (‐6.0 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD161<sup>+</sup> CD4<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (‐0.57 to 1.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD85j<sup>+</sup>CD8<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.64 (‐0.18 to 5.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.066</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>After stimulation with anti‐CD3/CD28 for 5 days followed by stimulation for 4 hours with phorbol myristate acetate and ionomycin </p> <p><sup>b</sup>Absence of immune stimulation </p> <p>CD: mature T‐helper cells express the surface protein CD4 and are referred to as CD4 T cells </p> <p>IFN‐γ: interferon‐gamma</p> <p>IL: interleukin</p> <p>T cells: T‐helper cells</p> </div> </div> </section> </section> <section id="CD008422-sec-0080"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p>We did not perform any predefined subgroup analyses (i.e. age, gender, type of MS, country of residence, disease‐modifying drug or immunomodulatory co‐therapy, serum 25(OH) vitamin D levels) nor sensitivity analyses, as we included an insufficient number of studies in this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008422-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008422-sec-0081">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008422-sec-0162">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008422-sec-0081"></div> <section id="CD008422-sec-0082"> <h3 class="title" id="CD008422-sec-0082">Summary of main results</h3> <p>This updated review included 12 randomised controlled trials (RCTs) (with 933 participants) comparing the effects of different doses of vitamin D supplements in the form of vitamin D₃ or vitamin D₂ versus placebo in people with multiple sclerosis (MS) at a median of 52 weeks' follow‐up. </p> <p>Data on annualised relapse rate (ARR) over the 52 weeks from randomisation were available from five RCTs and 417 participants. We found that vitamin D supplements had no clear effect on reduction of ARR in participants with MS who were receiving disease‐modifying drugs. Based on the GRADE approach, we assessed our confidence in the evidence for this result as very low owing to substantial risks of bias and imprecision. Assessment of disability progression was based on serial in‐trial changes in the Expanded Disability Status Scale (EDSS). Data on this primary outcome over 52 weeks from randomisation available from five RCTs and 221 participants show that vitamin D supplements were not effective in preventing worsening of disability. However, this finding should be interpreted with caution because we graded our confidence in the result as ’very low’ according to the GRADE approach. Information on effects of vitamin D on magnetic resonance imaging (MRI) lesions was available only for the number of MRI gadolinium‐enhancing T1 lesions that were reported over 26 weeks in two studies (82 participants) and over 52 weeks in two other studies (256 participants). Vitamin D supplements had no effect on reduction of MRI gadolinium‐enhancing lesions compared with placebo at both times. Vitamin D had very uncertain effects on health‐related quality of life; evidence for this outcome was limited. We found low‐certainty evidence showing the absence of serious adverse events (SAEs) reported in eight studies with 621 participants. Vitamin D alone or combined with calcium supplements did not increase nephrolithiasis and had no clear effects on SAEs nor on other minor adverse events, as reported in the studies included in this review. However, information on adverse events was scanty and was poorly reported. None of the included studies reported numbers of participants experiencing changes in EDSS score and time to first treated relapse. </p> <p>In terms of secondary outcomes, vitamin D had no effect on bone mineral density changes and very uncertain effects on fatigue. High‐dosage regimens of vitamin D seem more effective in achieving serum 25‐hydroxyvitamin D levels at or above vitamin D adequacy (20 ng/mL). Seven included studies focused on cytokine levels, inflammatory marker levels, or T‐lymphocyte proliferation with no consistent pattern of change in these immunological outcomes after vitamin D supplementation. None of the included studies reported numbers of participants requiring hospitalisation, cognitive function, or psychological symptoms. </p> </section> <section id="CD008422-sec-0083"> <h3 class="title" id="CD008422-sec-0083">Overall completeness and applicability of evidence</h3> <p>In this updated review, we included all eligible randomised trials up to October 2017. Four trials were conducted in Iran (upper middle income), and the other eight in high‐income countries (Australia, Canada, Europe, Israel, and USA). Trials included participants of both genders. Most participants had relapsing‐remitting MS, so our confidence in concluding anything about patients with progressive MS is limited. The included trials examined vitamin D‐deficient participants and those who had adequate vitamin D levels at entry; we noted no substantial differences regarding this baseline condition in terms of effects of vitamin D on the outcomes assessed in this review. Eleven of the 12 included trials assessed vitamin D₃, so our major conclusions pertain to this intervention. </p> </section> <section id="CD008422-sec-0084"> <h3 class="title" id="CD008422-sec-0084">Quality of the evidence</h3> <p>Most of the included studies had major weaknesses. The most common flaws were inadequate or unclear method of allocation concealment, high dropout rates after randomisation, and imprecision. Using GRADE criteria, we considered the evidence to be of very low certainty for relapse rate, worsening of disability, and MRI gadolinium‐enhancing T1 lesions measured at 52 weeks' follow‐up, and of low certainty for serious and minor adverse events. Our review did not find evidence of benefit of vitamin D for patients with MS, but conservative interpretation of the results is warranted because they were reported by a few small trials that we considered to be at high risk of bias. </p> </section> <section id="CD008422-sec-0085"> <h3 class="title" id="CD008422-sec-0085">Potential biases in the review process</h3> <p>We attempted to limit bias in the review process by ensuring a comprehensive search for potentially eligible studies, which included searching major databases and clinical trial registries, which nevertheless resulted in the retrieval of few studies. The two review authors' independent assessments of study eligibility for inclusion in this review and recording of extracted data minimised the potential for additional biases beyond those detailed in the risk of bias tables. We found no strong evidence of heterogeneity in any of the primary outcome analyses, which may emphasise the consistency of our findings but might also raise concerns, given that treatment schemes and comparison groups were different among the included studies. The included studies used different forms, doses, and durations of vitamin D supplementation. Most used vitamin D₃, one trial tested vitamin D₂, and in three trials, participants in the comparator group were allowed to take low doses of vitamin D. Finally, the possible presence of reporting bias could not be totally excluded. </p> </section> <section id="CD008422-sec-0086"> <h3 class="title" id="CD008422-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>We found that vitamin D had no effect on MS clinical or MRI activity, although in view of the very low certainty of the evidence, these results should be interpreted with caution. Our findings are consistent with the conclusions of other published reviews (<a href="./references#CD008422-bbs2-0026" title="AutierP , BoniolM , PizotC , MullieP . Vitamin D status and ill health: a systematic review. Lancet. Diabetes &amp; Endocrinology2014;2(1):76-89. [PMID: 24622671]">Autier 2014</a>; <a href="./references#CD008422-bbs2-0029" title="Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK168998, 2016 March 10. [PMID: 27077158]">CADTH 2016</a>; <a href="./references#CD008422-bbs2-0036" title="GaneshA , ApelS , MetzL , PattenS . The case for vitamin D supplementation in multiple sclerosis. Multiple Sclerosis and Related Disorders2013;2(4):281-306. [PMID: 25877840]">Ganesh 2013</a>; <a href="./references#CD008422-bbs2-0038" title="HempelS , GrahamGD , FuN , EstradaE , ChenAY , Miake-LyeI , et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2017;23(4):513-24. [PMID: 28151074]">Hempel 2017</a>; <a href="./references#CD008422-bbs2-0042" title="JamesE , DobsonR , KuhleJ , BakerD , GiovannoniG , RamagopalanSV . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis (Houndmills, Basingstoke, England)2013;19(12):1571-9. [PMID: 23698130]">James 2013</a>; <a href="./references#CD008422-bbs2-0044" title="Khosravi-LarganiM , Pourvali-TalatappehP , RoustaAM , Karimi-KiviM , NorooziE , MahjoobA , et al. A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis. eNeurologicalSci2018;10:37-44. [PMID: 29736427]">Khosravi‐Largani 2018</a>; <a href="./references#CD008422-bbs2-0063" title="Pozuelo-MoyanoB , Benito-LeonJ , MitchellAJ , Hernandez-GallegoJ . A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology2013;40(3):147-53. [PMID: 23257784]">Pozuelo‐Moyano 2013</a>; <a href="./references#CD008422-bbs2-0079" title="ZhengC , HeL , LiuL , ZhuJ , JinT . The efficacy of vitamin D in multiple sclerosis: a meta-analysis. MultIple Sclerosis and Related Disorders2018;23:56-61. [PMID: 29778041]">Zheng 2018</a>). <a href="./references#CD008422-bbs2-0029" title="Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Vitamin D for the Treatment or Prevention of Multiple Sclerosis: A Review of the Clinical Effectiveness [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK168998, 2016 March 10. [PMID: 27077158]">CADTH 2016</a> included four systematic reviews, eight RCTs, and three non‐randomised studies on the clinical effectiveness of vitamin D supplementation for prevention or treatment of MS. Evidence for most clinical outcomes was judged as limited and often conflicting owing to substantial heterogeneity between studies. Review authors concluded that results of treatment of MS with vitamin D were inconsistent, with most evidence suggesting no effect on disability scores or relapse rates. Researchers reported both positive and negative results for immunological factors, imaging studies, and functional outcomes. Safety data suggest that high‐dose vitamin D was well tolerated and was associated with minimal risk. <a href="./references#CD008422-bbs2-0079" title="ZhengC , HeL , LiuL , ZhuJ , JinT . The efficacy of vitamin D in multiple sclerosis: a meta-analysis. MultIple Sclerosis and Related Disorders2018;23:56-61. [PMID: 29778041]">Zheng 2018</a> published a systematic review that included six RCTs (all of them included in our review) published up to October 2017 (with 337 participants) reporting that vitamin D as add‐on treatment had no significant therapeutic effect on MS according to EDSS score (six RCTs; 318 participants; mean difference (MD) ‐0.01, 95% CI ‐0.34 to 0.33), but it increased the annualised relapse rate compared with placebo (five RCTs; 259 participants; MD 0.05, 95% CI 0.01 to 0.1). Review authors concluded that vitamin D appeared to have no therapeutic effect on EDSS score or relapse rate in patients with MS. <a href="./references#CD008422-bbs2-0038" title="HempelS , GrahamGD , FuN , EstradaE , ChenAY , Miake-LyeI , et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2017;23(4):513-24. [PMID: 28151074]">Hempel 2017</a> conducted a systematic review including five RCTs (all of them included in our review) published up to March 2015 (with 295 participants). Review authors found that vitamin D as add‐on treatment had no significant effect on EDSS score (standardised mean difference ‐0.15, 95% CI ‐0.33 to 0.02). <a href="./references#CD008422-bbs2-0042" title="JamesE , DobsonR , KuhleJ , BakerD , GiovannoniG , RamagopalanSV . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis (Houndmills, Basingstoke, England)2013;19(12):1571-9. [PMID: 23698130]">James 2013</a> published a systematic review including five RCTs (all of them included in our review) published up to 28 September 2012 (with 254 participants). Review authors reported an overall odds ratio for recurrence of relapse of 0.98 (95% CI 0.44 to 2.17) and concluded that there was no significant association between treatment with high‐dose vitamin D and relative risk of relapse in MS. <a href="./references#CD008422-bbs2-0026" title="AutierP , BoniolM , PizotC , MullieP . Vitamin D status and ill health: a systematic review. Lancet. Diabetes &amp; Endocrinology2014;2(1):76-89. [PMID: 24622671]">Autier 2014</a> conducted an updated systematic review and meta‐analyses of vitamin D supplementation for non‐skeletal conditions published between 1 January 2013, and 31 May 2017, and searched for trials published at any time up to 21 May 2017, that were not included in the meta‐analyses they selected. This review included the meta‐analyses published by <a href="./references#CD008422-bbs2-0042" title="JamesE , DobsonR , KuhleJ , BakerD , GiovannoniG , RamagopalanSV . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis (Houndmills, Basingstoke, England)2013;19(12):1571-9. [PMID: 23698130]">James 2013</a> and <a href="./references#CD008422-bbs2-0038" title="HempelS , GrahamGD , FuN , EstradaE , ChenAY , Miake-LyeI , et al. A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England)2017;23(4):513-24. [PMID: 28151074]">Hempel 2017</a> and concluded that vitamin D supplementation had no effects on relapse rates nor on changes in EDSS score over the trial duration. <a href="./references#CD008422-bbs2-0044" title="Khosravi-LarganiM , Pourvali-TalatappehP , RoustaAM , Karimi-KiviM , NorooziE , MahjoobA , et al. A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis. eNeurologicalSci2018;10:37-44. [PMID: 29736427]">Khosravi‐Largani 2018</a> published a narrative review and cited a previous review to conclude that available trials were not able to clearly support the hypothesis that vitamin D consumption can control MS outcomes (<a href="./references#CD008422-bbs2-0033" title="DörrJ , DöringA , PaulF . Can we prevent or treat multiple sclerosis by individualised vitamin D supply?EPMA Journal2013;4(1):4. [PMID: 23356351]">Dörr 2013</a>). <a href="./references#CD008422-bbs2-0036" title="GaneshA , ApelS , MetzL , PattenS . The case for vitamin D supplementation in multiple sclerosis. Multiple Sclerosis and Related Disorders2013;2(4):281-306. [PMID: 25877840]">Ganesh 2013</a> and <a href="./references#CD008422-bbs2-0063" title="Pozuelo-MoyanoB , Benito-LeonJ , MitchellAJ , Hernandez-GallegoJ . A systematic review of randomized, double-blind, placebo-controlled trials examining the clinical efficacy of vitamin D in multiple sclerosis. Neuroepidemiology2013;40(3):147-53. [PMID: 23257784]">Pozuelo‐Moyano 2013</a> reported narratively that some individual trials in patients with unspecified MS phenotypes or with relapsing‐remitting MS reported no differences in relapse rates following high‐dose vitamin D treatment, and these review authors concluded that the evidence for vitamin D as a treatment for MS was inconclusive. </p> <p>Despite the growing body of evidence indicating that vitamin D is unlikely to be efficacious for people with MS, some study authors strongly support its use in MS (<a href="./references#CD008422-bbs2-0058" title="Pierrot-DeseillignyC , SouberbielleJC . Vitamin D and multiple sclerosis: an update. Multiple Sclerosis and Related Disorders2017;14:35-45. [PMID: 28619429]">Pierrot‐Deseilligny 2017</a>; <a href="./references#CD008422-bbs2-0078" title="WagnerCL , HollisBW , KotsaK , FakhouryH , KarrasSN . Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Reviews in Endocrine &amp; Metabolic Disorders2017;18(3):307-22. [PMID: 28214921]">Wagner 2017</a>), emphasising benefit reported by observational studies and its relatively low toxicity. For these researchers, the lack of benefit noted in most trials should be attributed to participants not sufficiently deficient in vitamin D at baseline or to inadequate supplementation or a too short treatment period, as well as to the low quality of studies. </p> <p>The discrepancy between epidemiological studies, which reported an association between low serum 25OHD concentration and MS, and randomised interventional trials, which did not find benefit of vitamin D supplementation for people with MS, can be explained by the assumption that low vitamin D is not a cause but a consequence of ill health. Inflammatory processes involved in disease occurrence and clinical course would reduce 25‐hydroxyvitamin D (25OHD), which would explain why low vitamin D status is reported in a wide range of disorders (<a href="./references#CD008422-bbs2-0026" title="AutierP , BoniolM , PizotC , MullieP . Vitamin D status and ill health: a systematic review. Lancet. Diabetes &amp; Endocrinology2014;2(1):76-89. [PMID: 24622671]">Autier 2014</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008422-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008422-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008422-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008422-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 1: Annualised relapse rate" data-id="CD008422-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 1: Annualised relapse rate</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 2: EDSS" data-id="CD008422-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 2: EDSS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 3: Number of MRI gadolinium‐enhancing T1 lesions" data-id="CD008422-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 3: Number of MRI gadolinium‐enhancing T1 lesions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 4: QOL" data-id="CD008422-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 4: QOL</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 5: Serious adverse events" data-id="CD008422-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 5: Serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008422-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/urn:x-wiley:14651858:media:CD008422:CD008422-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vitamin D vs placebo, Outcome 6: Minor adverse events" data-id="CD008422-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_t/tCD008422-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Vitamin D vs placebo, Outcome 6: Minor adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/media/CDSR/CD008422/image_n/nCD008422-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008422-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>[Vitamin D] compared with [Placebo] for [Multiple Sclerosis]</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> [People] with [Multiple Sclerosis] </p> <p><b>Settings:</b> [Centers providing care for PwMS] </p> <p><b>Intervention:</b> [Vitamin D] </p> <p><b>Comparison:</b> [Placebo] </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No. of participants<br/>(no. of studies)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <td align="center" class="headercell" colspan="1" rowspan="3" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Vitamin D</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Annualised relapse rate (ARR) (number of relapses per patient per year)</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ARR in the control group ranged from 0.28 to 0.45.<sup>a</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean ARR in the intervention group was 0.05 lower (0.17 lower to 0.07 higher).</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>417<br/>(5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,c</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Expanded Disability Status Scale (EDSS) score</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the control group ranged from 1.6 to 3.6 on a 0 to 10‐point scale (best to worst).<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean EDSS score in the intervention group was 0.25 lower (0.61 lower to 0.10 higher).</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221<br/>(5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,d</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MRI gadolinium‐enhancing T1 lesions</p> <p>Follow‐up: 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of MRI lesions in the control group ranged from 0.1 to 0.36.<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean number of MRI lesions in the intervention group was 0.02 higher (0.45 lower to 0.48 higher). </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b,e</sup><br/>very low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> <p>Follow‐up: range 26 to 52 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(10 events)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> <p>(19 events)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk difference 0.01 (‐0.03 to 0.04)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>f,g</sup><br/>low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Minor adverse events</p> <p>Follow‐up: range 26 to 96 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>37 per 100</p> <p><sup>(130 events)</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 100</p> <p>(143 events)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Risk difference 0.02 (‐0.02 to 0.06)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>701<br/>(8) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<sup>g,h</sup><br/>low </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/>ARR: annualised relapse rate; CI: confidence interval; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; PwMS: person with multiple sclerosis; SAE: serious adverse event </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect<br/><b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/><b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/><b>Very low quality:</b> we are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Source of assumed baseline risk was the range of outcomes in control groups of the trials included in the meta‐analysis </p> <p><sup>b</sup>Downgraded by two levels because studies considered at serious or unclear risk of selection bias, performance and detection bias, and attrition bias </p> <p><sup>c</sup>Downgraded by one level for imprecision: studied in only 5/12 studies not reaching the optimal information size </p> <p><sup>d</sup>Downgraded by one level for imprecision: studied in only five small studies; the 95% CI of the pooled estimate includes both reduction and increase in disability score with vitamin D </p> <p><sup>e</sup>Downgraded by one level for imprecision: studied in only 2 studies; the 95% CI of the pooled estimate includes both reduction and increase in MRI lesions with vitamin D </p> <p><sup>f</sup>Downgraded by one level for serious risk of selective reporting: 4/12 studies did not report SAEs </p> <p><sup>g</sup>Downgraded by one level for imprecision </p> <p><sup>h</sup>Downgraded by one level for serious risk of selective reporting: minor adverse events were not collected through a systematic assessment </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Arrhythmia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any disturbance of the normal rhythmic beating of the heart</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A small protein released by cells that has a specific effect on interactions or communications between cells, or on the behaviour of cells. Cytokines include interleukins, lymphokines, and cell signal molecules, such as tumour necrosis factor, and the interferons, which trigger inflammation and respond to infection </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Demyelination</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Damage to the myelin sheath of neurons</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metalloproteases</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteolytic enzymes whose catalytic mechanism involves a metal, important in many aspects of biology, ranging from cell proliferation, differentiation, and remodelling of the extracellular matrix (ECM) to vascularisation and cell migration </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nephrolithiasis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of forming stones in the kidney, or lower down in the urinary tract</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Osteoporosis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thinning of the bones with reduction in bone mass due to depletion of calcium and bone proteins </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phytohaemagglutinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proteins isolated from the bean. They are used mainly in the study of immune mechanisms and in cell culture </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Annualised relapse rate (ARR)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Vitamin D</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Control group</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study ID</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ARR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 to 0.24<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.02 to 0.18*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>95% confidence interval </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Annualised relapse rate (ARR)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events (SAEs)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VigantOL oil plus interferon beta‐1a (Rebif)</p> <p>Number of participants with at least 1 SAE out of 113 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo plus interferon beta‐1a (Rebif)</p> <p>Number of participants with at least 1 SAE out of 116 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with at least one SAE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/113 (15.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/116 (6.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cardiac disorders/failure</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disorders</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/113 (2.6%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cellulitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eye infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyelonephritis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overdose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/113 (7.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/116 (5.2%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Breast cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ovarian cancer</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/113</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/116 (0.9%)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Syncope</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menorrhagia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Uterine polyp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypertension</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/113 (0.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/116</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Events were not collected via systematic assessment.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Serious adverse events (SAEs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">25OHD levels at baseline and during the intervention with the range of vitamin D dose supplementation in the included trials</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study and country</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration (months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants included in trials (n)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Range of vitamin D₃ dose (µg)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline 25OHD in intervention groups (nmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25OHD during the intervention (nmol/L)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of clinical benefit outcomes assessed by trials (n)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of clinical benefit outcomes with significant improvement (n)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0001" title="AchironA , GivonU , MagalashviliD , DolevM , Liraz ZaltzmanS , KalronA , et al. Effect of alfacalcidol on multiple sclerosis-related fatigue: a randomized, double-blind placebo-controlled study. Multiple Sclerosis (Houndmills, Basingstoke, England)2015;21(6):767-75. [PMID: 25344375]">Achiron 2015</a> Israel </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0002" title="AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . High dose vitamin D intake and quality of life in relapsing-remitting multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neurological Research2016;38(10):888-92. AshtariF , ToghianifarN , Zarkesh-EsfahaniSH , MansourianM . Short-term effect of high-dose vitamin D on the level of Interleukin 10 in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Neuroimmunomodulation2015;22(6):400-4. ToghianifarN , AshtariF , Zarkesh-EsfahaniSH , MansourianM . Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial. Journal of Neuroimmunology2015;15(285):125-8. ">Ashtari 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 every 5 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>70.56 ± 72.45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR) <br/>211.33 ± 107.00 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0003" title="BurtonJM , KimballS , ViethR , Bar-OrA , DoschHM , CheungR , et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology2010;74(23):1852-9. [DOI: 10.1212/WNL.0b013e3181e1cec2]KimballS , ViethR , DoschHM , Bar-OrA , CheungR , GagneD , et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism2011;96(9):2826-34. ">Burton 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1000 per day over 6 months followed by 250 per day for 3 months, then down‐titrated to 0 for the last 3 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>73 (38 to 146)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>413</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0004" title="EtemadifarM , JanghorbaniM . Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iranian Journal of Neurology2015;14(2):67-73. ">Etemadir 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1250 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>38.25 ± 7.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>84.25 ± 38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109.25 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>48.2 ± 13.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>122.6 ± 32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a> </p> <p>(Muris 2016)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167 per day for 4 weeks increased to 350 per day for 44 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>60 (38 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>231 (162 to 250)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (95% CI)</p> <p>55.56 (46.87 to 64.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (95% CI)</p> <p>123.17 (112.99 to 133.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7500 every month as intramuscular injection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 140</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0009" title="ShaygannejadV , JanghorbaniM , AshtariF , DehghanH . Effects of adjunct low-dose vitamin D on relapsing-remitting multiple sclerosis progression: preliminary findings of a randomized placebo-controlled trial. Multiple Sclerosis International2012;2012:1-7. [PMID: 22567287]">Shaygannejad 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calcitriol 0.25 per day increased to 0.5 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0010" title="AivoJ , LindsromBM , Soilu-HanninenM . A randomised, double-blind, placebo-controlled trial with vitamin D3 in MS: subgroup analysis of patients with baseline disease activity despite interferon treatment. Multiple Sclerosis International2012;2012:1-6. [PMID: 22919492]Soilu-HanninenM , AivoJ , LindstromBM , ElovaaraI , SumelahtiML , FarkkilaM , et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry2012;83(5):565-71. [PMID: 22362918]">Soilu‐Hanninen 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500 once a week</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>54 (19 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>110 (67 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 per day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>67 (22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD)</p> <p>166 (46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0012" title="SteinMS , LiuY , GrayOM , BakerJE , KolbeSC , DitchfieldMR , et al. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology2011;77(17):1611-8. [PMID: 22025459]">Stein 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D<b>₂</b> 150 per day </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>59 (47 to 61)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (IQR)</p> <p>120 (89 to 170)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>25OHD: 25‐hydroxyvitamin D</p> <p>CI: confidence interval</p> <p>IQR: interquartile ratio</p> <p>NR: not reported</p> <p>SD: standard deviation</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">25OHD levels at baseline and during the intervention with the range of vitamin D dose supplementation in the included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0005" title="GolanD , HalhalB , Glass-MarmorL , Staun-RamE , RozenbergO , LaviI , et al. Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurology2013;13:60. [PMID: 23767916]">Golan 2013</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ ‐ low dose (21 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ ‐ high dose (24 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 3 months of treatment</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐<i>γ</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20 (0.22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (1.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (1.3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Undetected</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐7 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.01 (3.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.14 (9.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (6.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (6.7)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Cytokine levels are given as means (SD).</p> <p>IFN‐<i>γ:</i> interferon gamma </p> <p>IL‐7: interleukin‐7</p> <p>IL‐10: interleukin‐10</p> <p>pg/mL: picogram/millilitre</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Serum inflammatory markers levels</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0008" title="MosayebiG , GhazaviA , GhasamiK , JandY , KokhaeiP . Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunological Investigations2011;40(6):627-39. [PMID: 21542721]">Mosayebi 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Vitamin D₃ (26 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Placebo (33 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>After 6 months</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐<i>γ</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2530 (230)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2250 (143)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2100 (98)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1980 (120)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (ρg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3600 (430)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4950 (530)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3430 (312)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3750 (325)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TGF‐<i>β</i> (ρg/mL) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (1.68)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.2 (2.4)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (1.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (2)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Cytokine levels are given as means (SD).</p> <p><sup>a</sup>P value = 0.0001. </p> <p>IFN‐<i>γ:</i> interferon gamma </p> <p>IL‐10: interleukin‐10</p> <p>pg/mL: picogram/millilitre</p> <p>TGF‐<i>β:</i> tumour growth factor beta </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Serum inflammatory markers levels</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Serum inflammatory marker levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Mean change in inflammation markers from baseline to end of study in the vitamin D group and the placebo group </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Røsjø 2015</p> <p>(sub‐reference under <a href="./references#CD008422-bbs2-0007" title="HolmoyT , LindstromJC , EriksenEF , SteffensenLH , KampmanMT . High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial. BMC Neurology2017;17(1):67. KampmanMT , SteffensenLH , MellgrenSI , JorgensenL . Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Multiple Sclerosis (Houndmills, Basingstoke, England)2012;18(8):1144-51. [PMID: 22354743]RøsjøE , SteffensenLH , JørgensenL , LindstrømJC , Šaltytė BenthJ , MichelsenAE , et al. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. Journal of Neurology2015;262(12):2713-21. SteffensenLH , JorgensenL , StraumeB , MellgrenSI , KampmanMT . Can vitamin D supplementation prevent bone loss in persons with MS? A placebo-controlled trial. Journal of Neurology2011;258(9):1624-31. ">Kampman 2012</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vitamin D₃ (36 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (32 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Group difference</p> <p>crude change (P value)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ALCAM (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (31)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (22)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5 (0.130)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CCL21 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (129)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (115)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (0.284)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CXCL16 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (224)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 (242)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5 (0.763)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐1Ra (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98 (478)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐10 (115)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108 (0.175)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MMP‐9 (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170 (464)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (529)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86 (0.719)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPG (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (307)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐33 (228)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76 (0.390)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPN (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.4 (3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.0 (2.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.252)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTX3 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐39 (566)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐95 (458)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (0.638)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sFRP3 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (3775)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129 (736)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐115 (0.995)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>sTND‐r1 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 (164)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83 (139)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (0.589)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TGF‐β1 (ng/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0 (2.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.1 (2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.1 (0.717)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Levels of markers are given as mean change (SD); P value calculated by the Mann–Whitney test. </p> <p>ALCAM: activated leucocyte cell adhesion molecule</p> <p>CCL21: chemokine (C–C motif) ligand 21</p> <p>CXCL16: chemokine (C–X–C motif) ligand 16</p> <p>IL‐1Ra: interleukin‐1 receptor antagonist</p> <p>MMP‐9: matrix metalloproteinase‐9</p> <p>ng/mL: nanogram/millilitre</p> <p>OPG: osteoprotegerin</p> <p>OPN: osteopontin</p> <p>pg/mL: picogram/millilitre</p> <p>PTX3: pentraxin 3</p> <p>sFRP3: secreted frizzled‐related protein 3</p> <p>sTND‐r1: soluble tumour necrosis factor receptor 1</p> <p>TGF‐β1: transforming growth factor beta 1</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Serum inflammatory marker levels</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serum inflammatory markers levels</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muris 2016</p> <p>(sub‐reference under <a href="./references#CD008422-bbs2-0006" title="HuppertsR . Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR). https://clinicaltrials.gov/ct2/show/NCT01285401 November 28, 2016 (last update posted). MurisAH , SmoldersJ , RolfL , ThewissenM , HuppertsR , DamoiseauxJ . Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. Journal of Neuroimmunology2016;300:47-56. SmoldersJ , HuppertsR , BarkhofF , GrimaldiLM , HolmoyT , KillesteinJ , et al. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. Journal of the Neurological Sciences2011;311(1-2):44-9. [PMID: 21620416]">Hupperts 2016</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Effect of vitamin D₃ supplementation on cytokine production</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marker</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Placebo plus IFN beta (Rebif) (23 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p>Vitamin D₃ plus IFN‐beta (Rebif) (30 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Log ratio</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Week 48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐10 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>713.9 (397.5 to 1319.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>806.1 (391.7 to 1618.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>913.8 (646.3 to 1431.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>934.3 (548.1 to 1388.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐4 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.6 to 3.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8 (0.7 to 2.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.8 to 4.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (0.8 to 2.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.87</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐5 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54.4 (22.5 to 171.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105.5 (52.5 to 335.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.9(45.4 to 134.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75.6 (45.8 to 145.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1451.4 (898.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1365.4 (877.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1673.1 (846.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1562.4 (798.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐17 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1112.2 (540.6 to 1713.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1181.0 (683.4 to 2408.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>825.0 (456.4 to 2311.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1233.1 (582.5 to 2504.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.76</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐22 (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261.3 (128.6 to 302.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132.1 (58.0 to 434.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181.8 (123.3 to 502.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234.3 (116.7 to 390.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GM‐CSF (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>674.5 (391.3 to 903.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>843.9 (406.3 to 1456.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>737.4 (474.6 to 1054.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765.7 (495.7 to 1038.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TNF‐α (pg/mL)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499.3 (196.1 to 800.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>765.6 (479.7 to 1080.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>676.1 (434.7 to 1022.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>897.2 (428.2 to 1394.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LAP (pg/mL))</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>543.1 (410.2 to 674.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>894.6 (689.1 to 1097.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.001</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>762.0 (527.0 to 907.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>753.9 (549.8 to 942.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ/IL‐5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.8 (3.6 to 50.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (11.9 to 35.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.9 (2.4 to 28.6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.1 (5.7 to 34.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Cytokine production in supernatant of anti‐CD3 stimulated peripheral blood mononuclear cells in participants included in this review. Mean and standard deviation (paired t test) or median and range (Wilcoxon Rank test) and P value of <sup>10</sup>log ratio week 48/week 0 (t test or Mann Whitney U test). </p> <p>GM‐CSF: granulocyte‐macrophage colony–stimulating factor</p> <p>IFN‐γ: interferon‐gamma</p> <p>IL: interleukin</p> <p>LAP: latency‐associated peptide</p> <p>pg/mL: picogram/millilitre</p> <p>TNF‐α: tumour necrosis factor‐α</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Serum inflammatory markers levels</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008422-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Immune cell subtype changes</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Immune cell subtype changes during the study, mean difference, % (95% CI)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008422-bbs2-0011" title="SotirchosES , BhargavaP , EcksteinC , HarenK , BaynesM , NtranosA , et al. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Neurology2016;86(4):382-90. ">Sotirchos 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comparison of change during study between<br/>groups, mean difference, % (95% CI) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IL‐17<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.68 (0.13 to 5.23)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.039</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.32 (‐2.89 to 13.53)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IFN‐γ<sup>+</sup> IL‐17<sup>+</sup>CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.21 (‐0.66 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Effector memory CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.24 (‐2.19 to 18.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Central memory CD4<sup>+</sup> T cells<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐8.08 (‐19.23 to 3.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.16</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naive CD4<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.99 (‐6.0 to 2.02)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD161<sup>+</sup> CD4<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (‐0.57 to 1.52)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.37</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CD85j<sup>+</sup>CD8<sup>+</sup> T cells<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.64 (‐0.18 to 5.46)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.066</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p><sup>a</sup>After stimulation with anti‐CD3/CD28 for 5 days followed by stimulation for 4 hours with phorbol myristate acetate and ionomycin </p> <p><sup>b</sup>Absence of immune stimulation </p> <p>CD: mature T‐helper cells express the surface protein CD4 and are referred to as CD4 T cells </p> <p>IFN‐γ: interferon‐gamma</p> <p>IL: interleukin</p> <p>T cells: T‐helper cells</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Immune cell subtype changes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/full#CD008422-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008422-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Annualised relapse rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Follow‐up at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.17, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Follow‐up at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.08, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 EDSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Follow‐up at 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.37, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Follow‐up at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.61, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Follow‐up at 96 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.21, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Number of MRI gadolinium‐enhancing T1 lesions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Follow‐up at 26 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.52, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Follow‐up at 52 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.45, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 QOL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 QOL (Physical)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 MSQOL (Mental)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 MSQOL (Sexual satisfaction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 MSQOL (Health change)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.5 FAMS QOL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.6 RAYS Physical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.7 RAYS Psychological</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.8 RAYS Social</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.03, 0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Minor adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>701</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.02, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin D vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008422.pub3/references#CD008422-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008422.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008422-note-0014">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008422-note-0024">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008422-note-0021">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD008422-note-0019">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD008422-note-0017">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD008422-note-0018">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD008422-note-0023">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008422-note-0016">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008422-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008422\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008422\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008422\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008422\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008422\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6zFwvAqw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008422.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008422.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008422.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008422.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008422.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715913642"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008422.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715913646"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008422.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d92b53dd49368',t:'MTc0MDcxNTkxNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 